Gene editing and CRISPR in the clinic: current and future perspectives
Matthew P. Hirakawa¹, Raga Krishnakumar¹, Jerilyn A. Timlin², James P. Carney³ and Kimberly S. Butler²,*

¹Systems Biology, Sandia National Laboratories, Livermore, CA 94551, USA
²Molecular and Microbiology, Sandia National Laboratories, Albuquerque, NM 87185, USA
³Advanced Materials Laboratory, Sandia National Laboratories, Albuquerque, NM 87185, USA
*Corresponding author

Keywords: CRISPR, Cas9, genome editing, clinical trial, zinc finger nuclease, gene activation, transcription activator-like effector nuclease
ABSTRACT

Genome editing technologies, particularly those based on zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and CRISPR/Cas9 are rapidly progressing into clinical trials. Most clinical use of CRISPR to date has focused on ex vivo gene editing of cells followed by their re-introduction back into the patient. The ex vivo editing approach is highly effective for many disease states, including cancers and sickle cell disease, but ideally genome editing would also be applied to diseases which require cell modification in vivo. However, in vivo use of CRISPR technologies can be confounded by problems such as off-target editing, inefficient or off-target delivery, and stimulation of counterproductive immune responses. Current research addressing these issues may provide new opportunities for use of CRISPR in the clinical space. In this review, we examine the current status and scientific basis of clinical trials featuring ZFNs, TALENs and CRISPR-based genome editing, the known limitations of CRISPR use in humans, and the rapidly developing CRISPR engineering space that should lay the groundwork for further translation to clinical application.
INTRODUCTION

Recent advances in biotechnology have revolutionized our ability to understand the genetic basis of human health. The advent of next-generation sequencing technologies and high throughput DNA microarrays have provided crucial tools to define the landscape of human genetic variation through large, international collaborative efforts (1, 2). Today, millions of human reference single nucleotide polymorphisms (SNPs) and structural variants from individuals worldwide are cataloged and publicly available for further investigation (3). The ability to quickly and thoroughly genotype individuals has enabled researchers to identify numerous genetic loci involved in common and complex diseases through genome-wide association studies (4, 5). Identifying genetic signatures associated with a wide variety of diseases in patients has been helpful in providing appropriate treatments and lifestyle changes to mitigate disease symptoms and improve the quality of life. With the rapid emergence of new genome editing tools, long-lasting or permanent mitigation of genetic diseases through selective modification of the human genome is now possible resulting in immense potential to improve human health.

In this review, we discuss the current state of gene editing technologies and their use as treatments for human disease. We place special emphasis on CRISPR (clustered regularly interspaced short palindromic repeat DNA sequences) based technologies, as they are quickly transforming the state of life science research around the world and progressing into clinical trials. The initial wave of modern-day genome editors [zinc-finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs)] have been evaluated in clinical trials to some extent, but use of these technologies has been limited due to the need for difficult and
laborious engineering of a new version of the editing protein for each new target in the genome (6-8). Most recently, CRISPR, a naturally occurring prokaryotic immune system that evolved across diverse bacteria and archaea to protect themselves from invading viruses (9, 10) has been re-purposed into powerful gene editing tools that function efficiently in diverse organisms including humans (11). In brief, CRISPR-editing involves the use of CRISPR-associated (Cas) enzymes that target and cleave specific nucleic acid sequences. There are numerous identified CRISPR systems, each of which have distinct nucleic acid binding requirements and enzymatic activities, however the majority of CRISPR-based applications to date utilize Cas9 from Streptococcus pyogenes (spCas9) (12). To target specific DNA sequences, Cas9 utilizes a CRISPR RNA (crRNA) with a 20 nucleotide complimentary sequence to the target sequence, and a trans-activating crRNA (tracrRNA) scaffold that is recognized by the Cas9 protein (13-15). Importantly, the crRNA and tracrRNA can be fused to form a single guide RNA (sgRNA) chimera that retains the ability to target and cleave specific nucleic acid target sequences (16). In contrast to early ZFN and TALEN-based editors, CRISPR-based systems require only alteration of the 20 nucleotide target sequence of the sgRNA in order to specifically target a new site in the genome, making the transition between gene targets far more efficient. Because of this, CRISPR-based systems are quickly transforming the state of life science research around the world and progressing into clinical trials. Comprehensive reviews of the history, function, and diversity of ZFN, TALEN, and CRISPR editors have been the subject of many prior reviews and the reader is referred there for introductory material about the function of these powerful editing technologies (6, 12, 17).
In this review, we will first discuss the state of gene editing technologies and their use as treatments for human disease with a specific focus on CRISPR-based therapies that are currently being tested in ongoing clinical trials. Second, we will present the known limitations for in vivo use of gene editors which include off-target effects, delivery issues, and immunogenicity of gene editing molecules. Given the rapid progression of gene editing tools, there are a number of solutions in the research and preclinical stages of development that have future potential to address these limitations for clinical use in humans. To conclude this review, we will discuss newly developed technologies that hold promise to address the limitations of current gene editors for clinical use that include the development of new delivery vehicles to direct gene editors to specific tissues, hyperaccurate CRISPR systems that decrease off-target effects, and gene editing tools that modulate the reversible control of gene expression and epigenetics.

CLINICAL TRIALS WITH GENE EDITORS

The US clinical trials database (clinicaltrials.gov) contains all studies which meet the definition of an “applicable clinical trial” initiated on or after September 27, 2007 or continuing beyond December 26, 2007. In addition to trials required to register, voluntary registration is also accepted; studies conducted outside the US, and those which may meet one of the conditions in the future, often register voluntarily. We searched the US clinical trials database (1/01/2020) for any trial containing at least one of the following terms: CRISPR, Cas9, Cas12, Cas13, ZFN, zinc finger, gene edit, gene modification, and genome edit. Trials that did not use the genome editor as part of the therapeutic intervention were excluded from the analysis;
these included trials to create cell lines from patients using Cas9, use of patient cells to develop therapeutic strategies, but where the cells were not used as a therapeutic themselves; CRISPR use for genome sequencing; and surveys of opinions regarding human gene editing. This search identified 41 trials utilizing genome editing agents including ZFNs, TALENs and CRISPR/Cas9 for therapeutic interventions, no studies utilizing Cas12 or Cas13 have been registered (Table 1).

Genome editing agents have clinically been utilized in two ways (Figure 1): cells can be removed from the patient or donor and modified outside the body (ex vivo) followed by reinfusion into the patient or the genome editor itself can be injected into the patient (in vivo). Of the registered trials, 37 were ex vivo delivery and only 8 were in vivo delivery. Ex vivo delivery, where the cells are altered in the lab and then infused into the patient, primarily utilizes electroporation as the methodology, but transduction by adenovirus is also used. In vivo delivery has focused on both localized delivery and systemic delivery. Registered clinical trials have exclusively used C2C12, whereas later trials also used AAV, polymer mediated plasmid delivery, and electroporation. Choice of in vivo versus ex vivo delivery also changed over time (Figure 2C). For example, early trials exclusively used adenovirus based delivery, whereas later trials focused on C2C12. Segregating the data by delivery method also reveals change over time as well as number of trials. Separating the data by delivery method also reveals change over time (Figure 2A). The first registered trial is from 2009, and between 2009 and 2015 ≤2 trials were registered per year, all of which focused on ZFNs. However, in 2016 and 2017 the number of TALENs and Cas9 trials were registered, reflecting a change in the genome editing agent as well as number of trials. Separating the data by delivery method also reveals change over time.
trials with localized delivery prior to 2019 were focused on polymer mediated plasmid delivery of ZFNs, TALENs or Cas9 to the vagina. However, localized delivery sites are expanding with a new trial in 2019 proposing direct injection into the eye of Cas9 via AAV vector. To date, systemic delivery has been limited to IV based delivery of AAV using ZFN mediated addition of a gene to hepatocytes.

**Ex vivo cell alteration and infusion trials**

Current clinical trials using *ex vivo* alteration by genome editors overwhelmingly focuses on the modification of T-cells to disrupt gene expression to either treat HIV-1 infection, or to enhance the efficacy of engineered T-cells to counter cancer. The earliest gene editing studies have been focused on disruption of the gene encoding CCR5, a major co-receptor that facilities HIV-1 entry into T-cells. This idea of gene editing CCR5 for curing or controlling HIV infection in patients was bolstered by the “Berlin Patient,” an HIV positive patient who was treated for Acute Myeloid Leukemia by bone marrow transplant in 2007. The physicians decided to perform the transplant with bone marrow from a donor who was homozygous for a CCR5 mutation known as CCR5 Δ32. This mutation results in loss of CCR5 expression on the cell surface, and, in this case of the Berlin Patient, resulted in a clinical cure of HIV infection (18, 19). CCR5 was chosen as an early target for gene editing because it has naturally occurring mutations that lead to loss of surface expression without any known severe adverse effects, and the effective loss of CCR5 was demonstrated to cure the patient of HIV. While the Berlin Patient underwent allogenic bone marrow transplant, in patients without leukemia it may be possible to disrupt the CCR5 gene *ex vivo* and then return the engineered cells to the patients via autologous stem cell transplant. ZFNs to knock out CCR5 in human cells were already under
development when the Berlin Patient was treated, and the first clinical trial was initiated in 2009 (20, 21). Additionally, although the majority of HIV therapy trials have focused on ZFNs, CRISPR/Cas9 has also been shown experimentally to provide a functional knock out of CCR5 which conferred resistance to HIV infection (22, 23), and the first human clinical trial of Cas9 for CCR5 knockout was registered in 2017.

The use of CRISPR Cas9 in HIV also opens several new possibilities for HIV therapy. While The Berlin Patient was cured of HIV through transplantation with CCR5 Δ32 bone marrow, several other attempts to perform this type of cure have failed and other patients have had viral rebound (24, 25). One possible reason for viral relapse is that there are two main co-receptors used for HIV entry, CCR5 and CXCR4. While most new infections are caused by a CCR5 utilizing variant of HIV, many chronic patients have both CCR5 and CXCR4 utilizing variants (24). In pre-clinical studies, ZFNs have been developed for CXCR4 and have demonstrated utility together with CCR5-targeting ZFNs (26). Pre-clinical studies of CRISPR/Cas9 based strategies have also been used to successfully knock out both CCR5 and CXCR4, and this method can be more efficient than ZFNs as only multiple gRNAs, rather than multiple proteins, need to be delivered (27, 28). Cas9 also presents the potential to eradicate HIV-1 reservoirs through the disruption of integrated HIV-1 proviral DNA in a variety of cell types (25). One in vivo study demonstrated that AAV delivery of Cas9 and gRNAs resulted in deletion of a large section of the genome-integrated HIV-1 provirus in a variety of tissues (29). And finally, recent work demonstrated that a combination of gene editing, using AAV-delivered CRISPR components, with long-acting slow-effective release antiretroviral therapies (LASER ART) could clear latent infectious reservoirs of HIV-1 in humanized mice (30). While CXCR4 targeting, dual
targeting of CCR5 and CXCR4 and deletion of HIV provirus have not yet reached the clinical stage, the pre-clinical studies highlight where genome editors may take HIV-1 therapy in the future.

While HIV-1 therapy was the earliest gene editing clinical trial and remains a major focus, many of the recent trials have focused on tailoring T cells for adoptive cell transfer (ACT) for cancer. There are four types of ACT to which gene editing is being applied: general T cells, tumor-infiltrating lymphocytes (TILs), T cell receptor (TCR) bearing cells, and chimeric antigen receptor (CAR) bearing T cells (Figure 3). The first two types of ACT to which gene editing is being applied, general T cells and TILs, involves the natural, unaltered, T cell targeting with gene editing to knock out a gene of interest. The second two ACT types, TCR and CAR modified T cells, involve genetically altering T cells via gene transfer in order to direct them to target cells of interest, and then further altered these cells by gene editing. Gene editing is being applied to ACT in several ways: To enhance survival after transfer, increase efficacy, prevent self-targeting, or develop universal T cells.

The earliest clinical trial utilizing CRISPR (NCT02793856) focused on collecting general T cells from peripheral blood and utilizing Cas9 to knock out the programmed cell death protein 1 (PD-1) gene. PD-1 is a protein found on the surface of T cells that negatively regulates T cell activation upon interaction with its ligand, PD-L1. High expression of PD-1 on the T cell surface accelerates T cell tolerance and exhaustion, limiting the efficacy of T cells against tumors. The primary safety concern with the first CRISPR trial was that use of general, non-specific T cells, rather than TILs collected directly from the patient’s tumors, might lead to a general overactivation of the patient’s immune system (31). While the concern is valid, and toxicity due
to anti-PD-1 and anti-PD-L1 therapies is a known issue (32), systemic therapy with PD-1 and PD-L1 blockers has been approved by the FDA for a variety of cancers (33), which the researchers felt mitigated the concern (31). The data from this first in human CRISPR trial reported thus far indicate no major adverse events; the trial was not designed to examine efficacy, however, so the effectiveness of this therapy is currently unknown (34, 35).

One major limitation to the first CRISPR clinical study is that the collected T cells are not enriched for cells likely to respond to the tumor cells. One method around this is the use of TILs collected directly from tumor resections. TIL therapy has a long history of clinical trials in melanoma (36), including long-term robust patient response, and is being developed for other cancers including cervical, ovarian, kidney, gastrointestinal, and head and neck cancers (37). Two TIL clinical trials to treat gastrointestinal cancer involve the collection of TILs from patient tumors and enhancing their antitumor efficiency through knock out of the gene Cish. TILs capable of targeting gastrointestinal cancer cells have been found in patients (38); however, Cish, a member of the suppressor of cytokine signaling (SOCS) family, has been shown to block the avidity of the TILs and reduce their activity against cancer (39). In a mouse model, knock out of the Cish gene in TILs led to increased expansion and responsiveness, leading to tumor regression (39). Furthermore, pre-clinical studies of ZFN mediated knock out of PD-1 in TILs for treatment of melanoma suggest that clinical trials using TILs with gene knockouts will be pursued in the future (40).

While the trials on TILs and general T cell gene editing focused on modifying naturally targeted T cells, the majority of ex vivo gene editing trials focus on using gene editors to enhance TCR and CAR engineered T cells (Figure 3A-C). Engineering the T cell recognition
through either the addition of a specific TCR or CAR to T cells circumvents several of the issues presented with TILs: first, not all patients have tumor-responsive T cells; second, these cells must be collected from surgical resections of tumors; and finally, there is no control over the targeted cancer antigen. TCR engineered T cells are based on transferring the genes encoding the α and β chains of a TCR specific to an antigen unique to, or overexpressed in, tumor cells into collected T cells that are then reinfused into the patient. In contrast, CARs are artificial chimeric receptors created to target cell surface markers on cancer cells. CARs are artificial receptors consisting of an external single-chain variable fragment (scFv) created from the variable regions of the heavy and light chains of antibodies for target specificity and internal T cell signaling domains leading to T cell activation upon scFv binding (41, 42). Similar to TCR engineering, CAR can be transferred in to collected T cells and then reinfused into the patient.

TCR and CAR engineered T cells each present unique advantages and challenges that gene editing can address (43). TCR engineered T cells have some advantages over CAR engineered T cells: the TCR is able to recognize intracellular proteins, including novel tumor antigens created by mutations, whereas CAR recognize only proteins present on the cell surface (43). However, the TCR recognizes peptides from intracellular proteins presented on the surface of the tumor cell in the major histocompatibility complex (MHC) class I molecules, and loss or downregulation of MHC molecules is a major source of tumor escape from immune surveillance which could limit the efficacy of TCR based therapies (44). CAR T cell recognition of target is independent of MHC expression, but limited to cell surface markers, which are commonly present on both diseased and normal cells, which can limit the utility of CAR T cell therapy (43).

Both TCR and CAR T based therapy has been pursued independent of gene editing, but gene
editing is opening new possibilities for enhancing immune therapy and will be discussed in more detail.

A number of TCRs that mediate T cell targeting of tumor cells have been identified and tested in clinical trials (45). One of the most promising of these TCRs is NY-ESO-1 (46). T cells engineered to express the NY-ESO-1 TCR have been used as effective therapy for melanoma, synovial cell carcinoma, and myeloma (45). One potential limitation to TCR therapy is the presence of the endogenous TCR α and β chains, which could pair with the engineered TCR α and β chains to create heterologous pairs. These heterologous pairs might reduce efficacy due to their inability to recognize the intended target, and cause toxicity due to recognition of unintended targets (47). The one registered gene editing trial to date (NCT03399448) which focuses on engineered TCRs uses CRISPR/Cas9 to knock out the endogenous TCR α and β chains (to remove the potential for heterologous TCR pairings) as well as PD-1 (to enhance TCR engineered T cell efficacy).

The majority of ex vivo gene editing trials focus on the enhancement of CAR engineered T cell therapy. CAR T cell therapy is the first form of gene transfer therapy to gain FDA approval, with two approved therapeutics, Tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta or Axi-Cell) for CD19 positive refractory pre-B cell acute lymphoblastic leukemia and diffuse large B cell lymphoma, respectively (43, 48). While both approved therapeutics target B cell malignancies, CAR T therapy represents an extremely large clinical trial space, with over 250 clinical trials in a wide variety of cancers currently underway (43, 49). Of these clinical trials, a number of them include gene editors to further enhance the CAR engineered T cells. Delivery of the CAR gene into T cells is mediated by gamma retroviral or lentiviral vectors; the advantage...
of these delivery systems is a high rate of gene transfer and stable expression of the CAR. However, these viral vectors integrate the CAR randomly into the genome, which can lead to varied CAR expression, insertional mutagenesis, overexpression of adjacent genes, and disruption of genes at the site of integration. While evidence of these issues has yet to been seen in CAR therapy (50), insertional oncogenesis and overexpression of adjacent genes have been seen in a human gene therapy trials using these viral vectors (51-55). One potential method around this is to direct where the CAR is inserted into the genome. Disruption of the TCR α constant (TRAC) locus has been demonstrated using TALENs, Cas9, and megaTAL Nucleases, with both TALENs and Cas9 being highly effective at disrupting TRAC expression and thereby reducing TCR expression on the T cell surface (56). Recently, this ability has been expanded to allow specific insertion of the CAR into the TRAC locus using Cas9 or TALENs (57-59). Integration of the CAR into the TRAC locus increased CAR T cell anti-tumor activity in mice models. The insertion of the CAR into the TRAC locus has the advantage of also disrupting the native TCR surface expression, which reduces the likelihood of graft-versus-host disease (GvHD) and increases the safety of allogenic CAR T therapy (60). This idea forms the basis for the clinical trial NCT03398967, which proposes to integrate two CARs (to CD19 and either CD20 or CD22) into the TRAC locus for allogenic ACT. The created cells will lack native TCR expression, which will facilitate allogenic ACT; and the dual targeting is hoped to prevent the relapse seen in CD19 CAR T therapy, where the cells lose CD19 expression by utilizing two surface targets (48, 61).

A number of clinical trials are focused on the creation of universal CAR T cells, through knock out of the TCR through removal of TRAC alone or of the TRAC and TCR β constant (TRBC)
loci. Removal of the TCR should prevent the transferred T cells from recognizing host antigens, which leads to GvHD. However, the presence of human leukocyte antigen (HLA) system proteins on the surface of the transplanted T cells, if mismatched with the host, can lead to rapid rejection of the transplanted cells. Some of the studies aim to both prevent GvHD and rapid rejection. For example, the removal of β-2 microglobulin (B2M), which is necessary for HLA expression, in addition to TRAC and TRBC resulted in increased efficacy of CD19 CAR T cells compared to removal of the TCR alone in mice models (62, 63). The combined knockout of the TCR with B2M by Cas9 in CD19 CAR T therapy is currently being tested in clinical trial (NCT03166878).

Another gene commonly targeted for removal by gene editing agents in CAR therapy for leukemia is CD52. CD52 is the protein targeted by alemtuzumab, a chemotherapeutic agent commonly used in leukemia treatment, but which can also kill the transplanted CAR T cells. Removal of both the TCR (to prevent GvHD) and CD52 using TALENs allowed generation of allogenic CD19 CAR T cells that could be used in combination with alemtuzumab in a mouse model (64). The utility of these TALEN edited CD19 CAR T cells is the basis of three currently running clinical trials (NCT02735083, NCT02746952 and NCT02808442). Prior to initiation of these trials, two infants with relapsed refractory CD19+ B cell acute lymphoblastic leukemia were treated with TALEN-mediated CD52 and TCR knockout CD19 CAR T cells in combination with anti-CD52 therapy (58). Both infants achieved molecular remission and had lasting CD19 CAR T cell persistence. In addition to removing antigens targeted by chemotherapy agents, the ability to remove genes allows application of CAR T cell therapy to T cell malignancies through the removal of the targeted T cell surface marker. CD7 is highly expressed on a variety of T cell
malignancies, but expression of the CD7 CAR prevented CAR T cell expansion due to fratricide in culture. CD7 knockout through Cas9 resulted in efficient expansion of CD7 CAR T cells while retaining CD7 selective killing in a mouse model (65), and is the basis of a current clinical trial (NCT03690011).

Another common gene editing approach in CAR T cells is the knockout of PD-1, either alone or in combination with TCR knockout. Selective knockout of PD-1 in the therapeutic T cells may be advantageous over systemic anti-PD-1 therapy, which can have significant immune toxicities (66). Combination of CAR therapy with PD-1/PD-L1 blockade is currently being examined in clinical trials, and preliminary results from CD19 targeted CAR T cell therapy has shown limited toxicity and enhanced CAR T cell survival (67-69). The PD1 knockout by Cas9 has been shown to enhance the efficacy of CD19 and mesothelin CAR T cells in mouse models (70, 71). PD1 knockout has also been combined with the gene knockouts designed to create universal CAR T-cells (62, 63). Clinical trials using CRISPR/Cas9 editing in CAR T cells are underway, including PD1 knockout in combination with mesothelin CAR T cells without or with TCR knockout (NCT03747965 and NCT03545815, respectively), and with CD123 CAR T cells with CD52 knockout (NCT03190278 and NCT03203369).

Another focus for ex vivo gene editing trials is the treatment of two hemoglobinopathies, β-thalassemia and sickle cell disease. While gene therapy has previously been successfully applied to β-thalassemia, through lentiviral transfer of the β globin gene (HBB) (72), the concern remains that random integration might result in oncogenesis (73). Gene editing provides an alternative to viral delivery of intact genes for the treatment of β-thalassemia and sickle cell anemia. While a number of studies have focused on utilizing genome
editors to facilitate the correction of mutations in HBB, or to aid in site specific incorporation of an intact copy of HBB (74-78), others have focused on the editing ability alone. It has long been known that mutations resulting in persistence of fetal γ-globin expression (usually silenced at birth) reduce the debilitating effects of mutations in β-globin, including β-thalassemia and sickle cell disease (79). Genome editing has been utilized to recreate the large deletion which causes Hereditary Persistence of Fetal Hemoglobin (HPFH), and hematopoietic stem cells that were Cas9-edited to create HPFH show increased expression of fetal γ-globin (80). Other studies have focused on deleting the fetal globin repressor BCL11A, leading to increased fetal γ-globin expression. ZFN, TALEN, and Cas9 have all been applied to BCL11A knockout and ZFN-edited hematopoietic stem cells were able to engraft in mice and express fetal γ-globin (81, 82). Disruption of BCL11A in hematopoietic stem cells via ZFN or Cas9 followed by cell transplantation to treat β-thalassemia or sickle cell disease clinical trials are currently underway (NCT03432364, NCT03653247, NCT03655678 and NCT03745287).

**In vivo gene editing trials**

Clinical trials of genome editors delivered *in vivo* have also been initiated. The trials to date have focused on easily accessible tissues, such as the cervix, eye, and liver. The latter being the most likely place for the delivered editing agent to accumulate. The largest set of *in vivo* genome editing trials has focused on eradication of integrated E6 and E7 HPV genes in cervical cancer. While vaccines are now available for HPV, the vaccines do not provide therapeutic effect for those who have already developed cervical cancer (83). All of the trials to date have originated in China, starting with a trial in 2016 that proposed the use of ZFNs, but in 2017 both TALEN and Cas9 trials were also registered. These trials take advantage of the easy access to
the cervix through the vagina, and in each case the delivery vehicle is a polymer gel suppository, the safety of which was recently tested in animal models (84). Non-viral delivery of ZFNs, TALENs, or Cas9 targeting the integrated E7 oncogene reduced tumor burden in mouse models (85-87). While the clinical trials to date have focused on non-viral delivery, AAV delivery of Cas9 targeted to E6 and E7 has also been shown effective in xenograft models (88, 89). Targeting E6 and E7 with genome editors often directly results in cell death; however, targeting these genes can also increase the sensitivity of tumors to other modes of therapy, including chemotherapy and radiotherapy (83), providing an increased rationale for utilizing these genome editors. One particularly interesting study examined HPV16+ patient xenografts of anal cancer in immunodeficient mice followed by Cas9 targeting of E6 and E7 (88). This work demonstrated a significant reduction in tumor growth in mice (88), suggesting that the therapeutic utility of genome editors for HPV treatment extends beyond cervical cancer.

While the largest set of in vivo genome editing trials was focused on treatment of cervical cancer, early use of in vivo ZFN gene editors was aimed to treat hemophilia B by replacing disease causing mutations in the F9 gene, which causes a deficiency of blood coagulation factor IX (90, 91). While the traditional gene editing approach is to replace the damaged gene at its native locus, if transcription from the native locus is too low there may not be a therapeutic effect. To address this issue, a subsequent study utilized AAV vectors to deliver a pair of ZFNs targeting gene replacement constructs at the albumin locus, which functions as a safe harbor locus with high transcriptional activity (92). As the delivery of two targeted ZFNs and a cDNA requires three AAVs to hit the same cell after IV injection, utilizing a highly expressed ‘safe site’ in the genome is more likely to result in therapeutic levels of protein.
expression. A commonly used safe site for gene integration is the adeno-associated virus integration site 1 (AAVS1), which can also be targeted for gene integration by ZFNs (93, 94).

Another commonly used integration site is the albumin locus, which is an especially attractive site for genome integration of secreted proteins. Exon 1 of the albumin gene encodes a secreted peptide that is cleaved from the final albumin product, so the addition of the cDNA with a splice acceptor site into intron 1 allows the creation of a new protein combining the secretory peptide and the protein of interest (92). The initial work on this system showed the ability insert the cDNA and a number of proteins including Factor IX (hemophilia B), Factor VIII (hemophilia A), α-Galactosidase A (Fabry Disease), α-L-Iduronidase (Hurler Syndrome, a.k.a. mucopolysaccharidosis type I (MPS I)), Iduronate-2 Sulfatase (Hunter Syndrome, a.k.a. mucopolysaccharidosis type II (MPS II)), and Acid β-Glucosidase (Gaucher Disease) (92).

Treatment of animal models of hemophilia A and B resulted in significant improvement in blood clotting, and intervention in MPS I and II prevented or reduced neurocognitive deficit in young animals (92, 95, 96). Of these initial gene sets, replacement of Factor IX, α-L-Iduronidase, and Iduronate-2 Sulfatase for hemophilia B, MPS I and II have advanced to clinical trials. The early stage results from the MPS II study suggested the treatments were safe, but also showed very low rate of editing events and inconclusive therapeutic efficacy in the low and medium dose patients (97). Patient treatments are expected to continue through 2019, but future trials will likely focus on second generation ZFNs that may have increased activity in human liver cells (97).

Beyond the use of ZFNs, the first AAV Cas9 trial was registered in 2019. The trial utilizes AAV to deliver Cas9 to the eye as a cure for Leber congenital amaurosis type 10 (LCA10). LCA10
is an ideal candidate for Cas9 therapy, as the most common LCA10 causing mutation occurs within an intron of the CEP290 gene, creating a novel splice site which alters the mRNA to create a premature stop codon (98). The treatment utilizes two sgRNAs which together mediate loss of part of the intron or inversion of this partial intron, either of which results in normal expression of CEP290 protein in patient cells. Furthermore, the eye is readily accessible, and subretinal injection in mice and primates resulted in sustained gene editing at a level expected to be therapeutic in humans (98).

**Clinical trials with inactive nucleases for transcriptional activation**

Another interesting aspect is the use of ZFNs, TALENs and Cas9 with inactive or absent nuclease function to allow semi-specific transcriptional activation or suppression. The advantage of this approach is that sequence specificity can be retained for targeted gene activation or inactivation without causing permanent alteration to the genome. From a clinical standpoint, this can reduce the concern about creating unwanted mutations as the DNA remains intact while still allowing alteration in gene expression. While the initial studies were limited to Zinc Finger Protein (ZFP) based transcription factors for activation of VEGF expression (Table 2), these studies suggest a path forward for more recent transcriptional activators and epigenome editors, based on deactivated Cas9 (dCas9), ZFPs and Transcription activator-like effector proteins (TALEs), which can be used to not only modulate transcription temporarily but also alter genome structure through methylation and acetylation to allow permanent changes in gene transcription (11, 99, 100). Later in this review we will discuss the recent technological advances regarding CRISPR-based control of gene expression and the epigenome in greater detail.
Looking forward: upcoming areas for gene editor clinical trials

The genome editing landscape is moving very quickly and a number of potential therapies beyond those currently in clinical trial are rapidly approaching the clinical trial space. Many of pharmaceutical companies put out regular updates on their development pipelines, giving insight into the likely coming trials. The majority of the anticipated ex vivo trials revolves around CAR T therapy and hemoglobinopathies (β-thalassemia and sickle cell disease) (101). Beyond these anticipated trials, another likely area of ex vivo clinical genome editor use are the monogenic primary immunodeficiencies (PIDs). Similar to the in vivo ZFN trials, treatment of the PIDs would require the insertion of a correct gene (or cDNA) copy. However, treatment of these PIDs is in some way ideal for genome editing, as the standard treatment is typically hematopoietic stem cell transplant, meaning the cells can be modified ex vivo which removes the in vivo delivery problem encountered with in vivo AAV trials (97). Furthermore, these diseases are severe enough that they are already the subject of gene therapy trials (102). Preclinical studies using genome editors and donor DNA have been demonstrated for three PIDs; X-linked severe combined immunodeficiency (SCID-X1) (103-105), chronic granulomatous disease (CGD) (106-111), and Wiskott-Aldrich syndrome (WAS) (112). Preclinical studies in SCID-X1 have focused on addition of a functional copy of interleukin-2 receptor subunit gamma (IL2RG) into the AAV1 safe harbor site or, more commonly, into native gene site (103-105). These studies were able to demonstrate functional gene expression and long-term engraftment in immunodeficient mouse models utilizing ZFNs (103, 105) and Cas9 (104) genome editing followed by integration of the provided therapeutic gene copy in SCID-X1 patient cells. Similar to the studies in SCID-X1, genome editing followed by integration of provided sequence to
insert functional gene copy has been demonstrated in CGD patient cells and resulted in long term engraftment in immunodeficient mice using TALENs (108), ZFNs (107, 108, 110), and Cas9 (106, 109), laying the groundwork for clinical trials in this space.

Beyond ex vivo trials, there are some promising advances in in vivo treatment of readily accessible tissues, such as the eye or ear. The eye is an attractive site for genome editing as direct access and self-contained nature of the eye reduces systemic effects. AAVs for delivery to the retina have already been identified and tested clinically, with one AAV based gene therapy already approved and tissue specific promoters are also known which can further limit expression to the cells of interest (113, 114). The first Cas9 clinical trial for blindness, treatment of LCA10, has already been registered (NCT03872479) and was discussed in the current trials section. Also under development is Cas9 therapy involving the knockout of the endogenous gene copies and replacement with a functional copy for autosomal dominant cone–rod dystrophy (CORD6) mediated blindness which has progressed to use in non-human primates (115). Beyond the initiated LCA10 trial and CORD6 experiments, CRISPR based therapeutics are being developed for a range of other inherited retinal disorders and multifactorial retinal diseases which has been reviewed elsewhere (116, 117). In addition to the eye, the ear is another site that also allows ready access for genome editing. While the studies in the ear have not progressed as far as the eye, correction of the USH2A gene responsible for both visual and hearing impairment in Usher syndrome has been shown in patient cells utilizing Cas9 and an DNA template (118). Beyond in vitro cell manipulation, Cas9 nickases with paired sgRNAs in combination with an oligonucleotide donor template editing of zygotes were able to prevent age-related hearing loss in an mouse model (119). Finally, Cas9 was used to selectively disrupt
the mutant allele of Tmc1 (transmembrane channel-like gene family 1) associated with autosomal dominant hearing loss while sparing the wild-type allele and preventing progressive hearing loss (120, 121).

In addition to easily accessible sites, liver targeted therapeutics are under development due to accumulation in liver of intravenously injected materials (101). Several groups have published on the potential to treat Alpha-1 Antitrypsin Deficiency (AATD) utilizing Cas9. Alpha-1 antitrypsin (AAT) is secreted by the liver, and if the mutant allele is present, the protein aggregates in hepatocytes causing liver fibrosis, cirrhosis and cancer and the reduction in circulating AAT also results in emphysema and Chronic Obstructive Pulmonary Disease (COPD) in the lungs. Cas9 has been used to knock out the mutant AAT gene or to knock in the normal gene in to a safe harbor site in mouse models (122-124). Research has shown that dual delivery of both Cas9 targeted to ATT in combination with a donor template will knockout the mutant allele and integrate the wild-type allele, leading to expression of the wild type AAT in mouse models (124, 125). In addition to therapeutics development to treat AATD in liver, non-viral, lipid nanoparticle (LNP) delivery of Cas9 facilitating hepatocyte selective targeting for the editing of mouse liver transthyretin gene, the mouse homolog of the human gene associated with Transthyretin Amyloidosis, which is caused by a buildup of misfolded transthyretin protein (126). The in vivo delivery resulted in a greater than 97% reduction in serum and liver protein levels and the reduction persisted for 12 months (126). The authors of this paper, also state this methodology can be applied to Hepatitis B treatment (101). Hepatitis B treatment by Cas9 and other genome editors, as well as treatment for other oncolytic viruses, has been reviewed extensively elsewhere (127-129).
While the previously discussed potential disease targets focus on diseases in tissues already under trial for genome editors, there are also development pipelines for new tissues and diseases, including Cystic Fibrosis (CF), Duchenne muscular dystrophy (DMD) (101), and spinal cord injuries (130). CF was the target of the earliest gene therapy trials as well as many ongoing gene therapy trials, one reason for this is the lungs can be readily targeted by inhalation (131, 132). However, to date, the efficacy has been too low in these trials for therapeutic effect (131, 132). Genome editors present a new possibility for therapeutic treatment of CF, although the low efficacy with gene therapy delivery agents studied to date may also apply to the delivery of genome editors. Repair of CF mutations has been demonstrated with ZFNs and Cas9 in vitro as well as in patient induced pluripotent stem cells (133-140), although testing in animal models has not yet been performed. CF is an interesting and challenging disease as the Cystic fibrosis transmembrane conductance regulator (CTFR) gene is very large and there are numerous mutations associated with the disease. Several gene editing strategies have been used to treat CF including Cas9 targeted removal of mutations that lead to nonfunctional protein splicing (135), ZFNs and Cas9 used to repair the ΔF508 mutation (134, 137-140), ZFNs used for the targeted addition of exons 11-27 of the CTFR gene into exon 11 as a functional gene correction (136), and Cas9 utilized to add a functional copy of the CTFR gene into an AAVS1 safe site (133).

Similar to CF, the gene encoding dystrophin, called DMD, is very large and there are numerous documented mutations along the entire gene that can cause DMD. The DMD gene is an interesting target for genome editing because a wide range of edit types can act as a functional cure including exon deletion, exon skipping, exon reframing and exon knock-in,
depending on the specific disease causing mutation present (141). While the use of Cas9 for DMD has been reviewed elsewhere (141), there are a few studies in this field worth highlighting specifically. The first is the use of Cas9 to correct the deltaE50-MD canine model of DMD, this study examined both localized muscle delivery and systemic delivery via AAV. Systemic delivery resulted in expression of dystrophin in multiple muscles, including cardiac muscle at rates near normal at 8 weeks post systemic delivery (142). While longer term studies are needed in larger animal models, such as canines, a long term study was recently completed in a mouse model of DMD. This study utilized systemic AAV delivery of Cas9 in neonatal mice and found a single dose administration resulted in sustained editing and dystrophin protein expression 1 year after treatment (143).

**Germline editing and CRISPR Babies**

The rapidly advancing CRISPR toolkit holds many promising developments towards advancement of clinical medicine, although there are several safety and ethical concerns still to be addressed. One of the areas of greatest concern is germline editing, which creates a heritable alteration in the genome (144, 145). While an in-depth discussion of the ethical concerns and governmental regulatory concerns raised by germline editing are beyond the scope of this review, the actions in this area have the potential for far reaching effects in clinical genome editing and public image of these technologies (145). We have therefore provided a brief overview of the technology as used in research and in humans (146).

Cas9 editing of zygotes has been applied to DMD treatment in a mouse model, creating a permanent and potentially inheritable change in the genome (147). The ability to edit zygotes
provides a pathway for eliminating fatal or debilitating monogenetic diseases and could act as a compliment to preimplantation genetic diagnosis (148, 149). This research has gone beyond animal models and editing of human zygotes has also been performed utilizing both non-viable and potentially viable embryos (146, 150-153). While the researchers publishing these embryo studies highlighted areas of concern as well as promise, such as the need for increased fidelity, specificity and reproducibility, more recently, CRISPR edited embryos were implanted and resulted in the birth of twins in China (149, 154). While it remains unclear if and exactly how the babies’ genes were modified, there has been a flurry of debate regarding germline editing (149, 154, 155). This event has created a push for a moratorium on editing human embryos and the World Health Organization announced the establishment of a committee to devise guidelines for Human Gene Editing (149).

ISSUES LIMITING IN VIVO CLINICAL USE OF CRISPR

While clinical trials have already begun, both ex vivo and in vivo in humans, there are still some issues that may limit the clinical use of CRISPR in vivo. The limiting issue which has received the most attention is the delivery problem: how do we accurately deliver CRISPR, control its activity and limit off-target events (156)? For example, while AAV delivery is advantageous for gene therapy as it provides the possibility of long-term expression, this may lead to undesirable effects as the CRISPR enzyme would be expressed indefinitely. Non-viral delivery may allow temporal control of CRISPR activity, but the efficacy has traditionally been lower than viral delivery, although recent work with LNPs shows promise for highly efficient non-viral vectors (126). Due to the diversity of delivery options; CRISPR Cas9 can be delivered
as DNA, RNA or ribonucleoprotein (RNP), a wide variety of delivery vehicles and methods have been developed and several reviews have focused on the methods to achieve delivery with both viral and non-viral vectors (17, 157). Beyond delivery to cells in general, the specificity of delivery is also important as in some cases a specific organ or cell type must be targeted. To date, most in vivo clinical trials have focused target tissues with direct access, such as the cervix or eye, or alterations in liver. As the field expands to more disease targets, the ability to target the therapy, either through controlled, tissue-specific expression of Cas9, or cell specific targeting will become more important. Other limitations to in vivo delivery, which have received less attention that the delivery issue, are the detection and consequences of off-target effects, and immunogenicity of CRISPR therapies.

**CRISPR immunogenicity**

*In vivo* delivery of CRISPR, both Cas9 and other CRISPR systems, can be immunogenic through 3 main pathways; innate immunity, humoral immunity or cellular immunity, illustrated in Figure 4 (158). The innate immune system utilizes pattern recognition receptors to recognize conserved features in microbes, including the recognition of foreign nucleic acids (159). This raises the possibility that mRNA or DNA encoding CRISPR or the gRNA could be recognized. Studies using *in vitro*-transcribed gRNA have been demonstrated to trigger the innate immune response in both human and mouse cells triggering interferon response and cell death (160, 161). This response could be tempered through the use of chemically synthesized gRNAs or through chemical modification of the *in vitro*-transcribed gRNAs (160, 161). While these studies show proof-of-principal, further studies are needed to identify the best method to avoid the innate immune response to both the gRNA, mRNA and DNA delivery.
Beyond innate immunity, antibodies to SaCas9 and SpCas9 have been found in human serum samples, suggesting a pre-existing immunity to Cas9 in a portion of the human population due to prior exposure to the two most currently used Cas9 sources, *S. aureus* and *S. pyogenes* (162, 163). These two studies found very different portions of the population to have preexisting antibodies, 10% or 78% to SaCas9 and 2.5% or 58% to SpCas9 (162, 163), suggesting some variability either in the testing or populations. Despite these differences, it is clear that a portion of the human population has preexisting antibodies to the two most commonly used Cas9 enzymes, which could affect the use of these Cas9 molecules *in vivo*. Furthermore, studies in animal models have shown that delivery of SaCas9 by AAV results in the development of anti-SaCas9 antibodies in adult mice after systemic delivery and in non-human primates after injection into the eye (115, 143). Similar to the findings with SaCas9 by AAV, systemic delivery of SpCas9 by Adenovirus also resulted in development of anti-SpCas9 antibodies in adult mice (164). The age of the animal appears to be important in the immune response development as systemic injection of neonatal mice with AAV-SaCas9 did not result in antibody development (143). While the development of antibodies to Cas9 may not be problematic for single dose therapy with Cas9, it could prevent repeated use. As both preexisting and developed immunity can occur, these factors may need to be monitored during clinical development of CRISPR therapeutics.

In addition to both innate immunity and humoral immunity, cellular immunity mediated by cytotoxic T cells can also be directed against Cas9 expressing cells. Examination of human blood samples has shown the presence of reactive T cells to both SaCas9 and SpCas9, with the percentage of responding population being 78% to SaCas9 and 67% or 96% to SpCas9,
depending on the study (162, 165). Similar to the humoral immunity studies, there is variability in the percentage of responding humans, but it is clear that many people may have cells capable of killing Cas9 transfected cells in vivo. In addition, animal studies have shown the development of cellular immunity to Cas9 after AAV delivery of SaCas9 and adenoviral delivery of SpCas9 in mouse models and AAV delivery of SaCas9 in non-human primates (115, 143, 164). As seen with antibody development, the age of the animal appears to be important, as systemic delivery of AAV-SaCas9 to neonatal mice did not cause the development of a reactive T cell response (143). The development of a T cell response could be problematic, as it could result in the destruction of Cas9 expressing cells in vivo, abrogating the therapeutic effect and potentially result in the therapy exacerbating a condition through eliminating the population of cells targeted for editing. It is possible that this effect could be mediated by immune suppression, however this would not be ideal for long term treatment, making controlled temporal presence of Cas9 important to prevent adverse immune effects.

The studies to date have shown that age may be an important mediator of the immune response. In addition to age, it is likely that the delivery vector will have a strong effect on the immunological response. In animal models, the delivery of Cas9 with adenoviral vectors, which are highly immunogenic, resulted in decrease of Cas9 expression overtime, no therapeutic effect, inflammation and hepatocellular toxicity. In comparison, delivery of Cas9 by plasmid resulted in lower gene correction but therapeutic effect suggesting edited hepatocyte survival (158). It is therefore important to determine and control the immune response to both Cas9 and the delivery vehicle for efficacious editing. One possible method to reduce the immunogenicity of Cas9 is the identify the epitopes leading to immune stimulation and
engineer the Cas9 protein to create a low immunogenicity Cas9. Preliminary studies in this area were able to identify the reactive residues and alteration of these residues did not abrogate SpCas9 editing (164), suggesting the potential to reduce the immunogenicity profile of Cas9 and enhance its therapeutic use (158).

**Off target effects**

An ideal gene editor would exhibit perfect specificity for the target sequence and cause no mutations to any other region of the genome. Unfortunately, CRISPR/Cas based editors (and other editors, such as ZFNs and TALENs) rarely achieve such a high standard. Off-target effects primarily arise from the sgRNA seed sequence or PAM sequences binding with sequence mismatches (1-5 bps have been shown to be tolerated) but can also be influenced by cell-type and the DNA repair pathways in a particular cell type. The reader is referred to Zhang et. al for a more thorough review of the mechanisms of CRISPR off target effects (166). Off-target effects were postulated early in the development of gene editors and recent advances have increased the sensitivity for detection of these effects. As a result, off-target effects have been shown in virtually all systems studied.

The presence of off-target effects does not necessarily prevent gene editing tools from succeeding in clinical applications. Off-target modifications could be tolerated for many treatments if they were random, showing no sequence bias, and the levels were at or below the random mutation frequencies. Additionally, while off-target effects may have significant consequences in specific cell types, like stem cells or neurons, they could be more tolerable in cells that are fully differentiated or those with short replicative lifespans. Ultimately, the treatment risk must be weighed with disease prognosis and the potential benefit. Currently
accepted clinical treatment methods for many diseases carry with them high risk including mutagenesis (e.g. cisplatin for cancer chemotherapy (167)). High risk of off-target modifications could be accepted for difficult to treat diseases especially where the overall prognosis is poor, provided the possible mutation risks were known.

Strategies for optimizing CRISPR specificity through improved design have resulted in software tools for predicting off-target sites and probabilities ranging in complexity from threshold-based to machine learning-enabled. Assays for detecting CRISPR off-target mutations have traditionally attempted to identify the double stranded breaks created when Cas9 cleaves the genome with a combination of DNA sequencing and bioinformatics. The assays vary in their approach and can suffer substantial bias due to PCR amplification. Approaches for predicting and detecting CRISPR off-target effects developed prior to 2015 are adequately reviewed in Zhang et. al. (166). Most recently this topic has been updated and expanded upon to include developments up through 2018 in a review by Gkazi which presents a concise summary of tools for quantifying off target modification from CRISPR/Cas9 in three categories, in silico (prediction), and in vitro and in vivo assays including advantages and disadvantages to each method (168). To avoid redundancy with these reviews, we limit our discussion here to several promising, newly emergent tools with potential for or direct application for assaying off-target effects in the clinic and refer the reader to Gkazi for information on additional tools and the historical evolution.

One area of interest in off target discovery are methods that can bridge both in vitro and in vivo gap in off-target detection. Keith Joung and coworkers have demonstrated a pipeline that bridges in vitro and in vivo to enable improved nuclease-based therapeutic strategies in a
recent publication (169). Their system, coined Verification of In Vivo Off-targets or VIVO, invokes a two-staged approach where an initial “discovery” step is performed in vitro to identify a large, inclusive set of potential off-target cleavage sites using Circularization for In vitro Reporting of CLeavage Effects (CIRCLE-seq). This initial step is followed by an in vivo confirmation step that identifies indel mutations in the potential set of sites. This pipeline is advantageous for examining the genome-wide specificities of CRISPR/Cas editors and identifying off-target effects. Although, not experimentally demonstrated in this initial publication, the approach is believed to be generalizable to non-CRISPR approaches and non-mammalian organisms (Supplementary discussion, (169))

Jacob Corn and coworkers recently reported a new assay, Discovery of In Situ Cas Off-targets and VERification by sequencing (DISCOVER-seq), for detecting off-target modifications to the genome (170). DISCOVER-seq operates differently than other off-target detection assays in that it monitors a protein involved in DNA repair, MRE11, to identify where genome edits have occurred rather than the double-stranded break itself. The use of a repair factor protein that is specifically and avidly recruited to a DSB site only during active DNA repair leads to a significant reduction in false-positives over prior methods like ChIP-seq that utilize Cas9 binding as a basis for detection. Importantly, MRE11 is broadly conserved across multiple species and expressed in many cell types. The method has been shown to be insensitive to differences in guide RNA formats and Cas enzyme orthologs. Together these features point to the potential of DISCOVER-seq to be a universal detection platform for identifying off-target mutations in vitro and in vivo. Typically, assays for CRISPR/Cas genome edits are accomplished using a variety of targeted PCR amplification followed by next-generation sequencing or next-
generation sequencing alone. These assays can be extremely sensitive to small edits such as indels, but inherently insensitive to detection of structural variations including large deletions, translocations and inversions. Unfortunately, the potential for structural rearrangements are important to measure as chromosome rearrangements can cause alterations in gene expression leading to clinical symptoms or even the development of cancer (171, 172).

Additionally, understanding the potential for structural alterations in chromosomes is required both for FDA approval and to the development of safe genome editors for clinical use. Recently, the Uni-directional Targeted Sequencing (UDiTaS) method was shown to successfully measure structural changes and indel events in one reaction (173). The basis for the method is a custom Tn5 transposon, a unique molecule identifier (UMI) barcode, and a pooling barcode which are assembled and used to tagment genomic DNA. Following amplification of target regions, two rounds of PCR are performed (one using the target primer and the second creating the Illumina sequencing library). The method was shown to be highly linear and sensitive, though it could be limited by bias during the amplification. While the UDiTaS method is designed for use in vitro, the ability to look at specific cell types, including primary cells, can define specific large and small genome alterations to monitor in in vivo studies and can provide necessary supplemental information on large scale genomic alterations caused by genome editors.

Similarly, CHAMP (Chip-Hybridization Association Mapping Platform), is an in vitro method that has been shown success profiling off-target CRIPSR-Cas binding on synthetic and importantly human genomic DNA (174). CHAMP utilizes a Mi-Seq flow cell which following DNA sequencing is repurposed for use as a spatially-addressable platform containing a library known (sequenced) DNA oligomers that can bind to Cas proteins. In combination with fluorescent
reporters on the DNA and the Cas protein and high throughput total internal reflection
fluorescence microscopy (TIRFM) each oligo on the chip is read out and the presence of both
fluorescent labels indicates that DNA sequence can bind the protein. This method can thus
provide quantitative profiling of off-target binding sites in the genomes of individual patients in
the clinic and with future development could also assay target cleavage in addition to binding.

Beyond off target effects in CRISPR editing and DNA interaction, recent research has
found unanticipated effects in protein expression and function after attempted CRISPR gene
knock outs (175). Combined RNA sequencing and triple-stage mass spectrometry was utilized
to examine the protein expression of 193 DNA verified CRISPR induced frameshift deletions and
demonstrated protein expression in one third of the targets. Closer examination found the
proteins were either N-terminally truncated or the product of skipping the editing exon,
creating a different protein isoform. Detailed analysis of three of the truncated proteins found
partial preservation of protein function. Additionally, recent studies have demonstrated that
the tumor suppressor p53 can inhibit CRISPR engineering in human cells by causing toxicity and
cell death as a result of DSB formation (176, 177). The inhibition of CRISPR activity by p53 is
particularly concerning as this can promote selection of p53-defective cells with increased
tumorigenic potential. Taken together, these studies and other studies of off target effects
reviewed elsewhere highlight the need to understand the biological effects of CRISPR use at the
DNA, RNA and protein level to prevent unintended effects of CRISPR clinical use of current gene
editors and the coming gene editing technologies.

COMING SOLUTIONS AND NOVEL GENE EDITING TECHNOLOGIES
Having surveyed the landscape of current CRISPR clinical trials, it is important to look forward to anticipate which of the novel CRISPR-based technologies currently in the pipeline are likely to be impactful in the clinic in the near future. In the following sections of this review, we identify and discuss a few areas of focus for future research that will likely have significant clinical impact.

**Hyperaccurate CRISPR systems**

As previously discussed, off-target effects of CRISPR systems are caused by a range of factors, including levels of the CRISPR complex, sgRNA sequence, PAM sequence and target genome structure/state(166, 178, 179). We will discuss efforts to reduce off-target effects by addressing a number of these factors to generate hyperaccurate CRISPR systems (Figure 5).

When the domain structure and function of an enzyme is known, rational design can be an effective and inexpensive way to rapidly produce high-efficiency alternatives to the canonical protein. With SpCas9, a number of studies have elucidated the structure-function relationships within the protein, opening up the door for mutation by rational design(180-184). Enhanced SpCas9 (eSpCas9) is a SpCas9 variant which neutralizes the positive charge of a nontarget strand groove located between the HNH (Histidine Asparagine Histidine), RuvC, and PAM-interacting domains in SpCas9. This decreased nontarget strand binding, likely allows for rehybridization between the target and nontarget DNA strands, which preferentially prevents sgRNA-DNA hybridization at weaker, non-specific interactions(185). Another example is SpCas9-HF1, which was designed by mutating four residues that are known to be involved in formation of non-specific DNA contacts. This resulted in a form of SpCas9 that retained over 85% of wild-type activity, but almost eliminated off-target effects(186). In yet another study,
the Doudna group demonstrate that a domain in SpCas9 of previously unknown function, REC3, binds to the RNA–DNA duplex and enables the docking of the HNH nuclease domain at the active site. They also show that both eSpCas9 and SpCas9-HF1 contain mutations in the REC3 domain that block the HNH nuclease domain in the inactive state (also called the ‘conformational checkpoint’) when bound to mismatched targets. This led them to rationally design a new hyperaccurate SpCas9, called HypaCas9, with mutations in this same REC3 domain that trigger this conformational checkpoint (with the help of another domain, REC2)(187). These studies demonstrate the usefulness of rational design experiments, where a few targeted mutations can yield significant gains in terms of specificity.

A limitation of rational design however is that, by definition, it is limited by what we know about the target protein, making it potentially limited in scope and inherently biased. The larger-scale unbiased alternative to rational design is directed evolution which, while being a lot more resource-intensive and having a smaller rate of success, can yield novel and unexpected variants of a protein. For example, Casini et al. targeted the same domain as the Doudna group, REC3, for generating a hyperaccurate version of SpCas9, but instead of choosing residues to mutate based on known structure, they performed random mutagenesis over this domain and set up a large-scale screen in yeast. Ultimately, they combined four beneficial mutations to create evoCas9, which they show has superior activity and specificity to both wild-type and rationally designed Cas9 (eSpCas9 and SpCas9-HF1)(188). Another group set up a one-step screen in E.coli by introducing a target gene from the human genome (EMX1) into the E.coli genome, a mismatched version of the target on a plasmid encoding a toxin, a mismatched sgRNA to EMX1 and a library of SpCas9 mutants. This allowed for an elegant method to select
SpCas9 mutants that caused cleavage of the toxin plasmid with the mismatched EMX1 (allowing for survival), but not the EMX1 in the *E.coli* genome (which would cleave the genomic DNA and cause cell death). Through this method, the authors identified a number of mutations not overlapping with any previously identified Cas9 variant and named their best mutant Sniper-Cas9 (157). A similar method in *E.coli* used an on-target sequence on a toxin plasmid and an off-target sequence on an antibiotic resistance-containing plasmid, with three different human genes, including EMX1. The authors were specifically screening for Cas9 that retained activity and specificity in the context of the RNP form, which is the form with the most precise dose control for introduction of CRISPR components in the context of a therapy or clinical trial (189). This revealed high-fidelity (HiFi) Cas9, containing a single point mutation (R691A) which the authors show resulted in a variant with high efficiency and specificity when delivered as an RNP in human CD34+ hematopoietic stem cells, compared with other high-fidelity Cas9 variants discussed here (189).

Phage-assisted continuous evolution (PACE) with three different PAM sequences on independent plasmids has also been used to expand the PAM specificity of SpCas9. The result, xCas9, harbors mutations near the DNA–sgRNA interface, and recognizes a wider range of PAMs while surprisingly also having decreased off-target effects compared with wild-type SpCas9 (190). This result shows that directed evolution can expand the PAM specificity without sacrificing target specificity, suggesting that there are still many improvements to CRISPR systems that can be explored which we may not intuitively deduct. Methodically-designed directed evolution, as exemplified in the studies above, are likely to be a critical component of designing increasingly efficient and accurate variants of CRISPR components, including other
Cas proteins such as SaCas9 and Cas12. Each new study discussed here demonstrates that their version of Cas9 has the highest activity and accuracy compared with its predecessors, which is encouraging in terms of achieving a safe and accurate version of Cas9 that can reliably be used as a therapeutic. However, it is important to remember that there might be cell-type- and delivery method-specific differences that can affect specificity and no comprehensive study comparing all of the Cas9 variants across all cell types and deliver methods has been performed. Therefore, each of these variants need to be individually tested for each desired application.

An alternative to introducing mutations in Cas9 to alter its function is creating fusions of Cas9 with other proteins such as programmable DNA-binding domains (pDBD), which can be used to enhance the specificity of Cas9. For example, early studies showed that a Cas9 fusion with the FokI nuclease (fCas9) requires the simultaneous binding of two monomeric fCas9s 15-25bp apart for cleavage, which greatly reduces off-target effects(191, 192). This is similar to the ‘paired nickase’ approach, in which instead of having a single Cas9 nuclease, successful cleavage requires two mutated Cas9 proteins (which are nickases) localized by two independent sgRNAs(193-195). A similar approach was utilized by Bolukbasi et al., where they examined the properties of fusions of SpCas9 with ZFPs and TALEs. Importantly, the authors simultaneously reduced the endogenous DNA-affinity of the Cas9, with the goal of broadening the sequence targeting range of the fusion protein, and show that this actually results in a significant increase in specificity (196). Another interesting approach to increasing specificity of Cas9 is to create a fusion with chemically regulated proteins such as dihydrofolate reductase (DHFR) or the estrogen receptor (ER50), which are stabilized by trimethoprim (TMP) or 4-hydroxytamoxifen.
respectively. In the absence of these chemicals, the fusion proteins are targeted for degradation, thus reducing off-target effects by limiting the availability of the protein(197). One disadvantage of fusion proteins is that they tend to be rather large, which can complicate delivery. Fusions of smaller Cas proteins (such as SaCas9 or Cas12a) with proteins that enhance targeting specificity could therefore be worth exploring. Fusion proteins are also further discussed in the context of base editors later in this review.

Until now, we have primarily focused on alterations to the protein component of CRISPR systems with the goal of increased specificity. However, parallel and equally justifiable efforts to increase the accuracy of CRISPR systems involve changing the structure of the sgRNA. The rules of sgRNA design are constantly evolving to improve specificity, with multiple groups contributing to this effort(195, 198-200). In addition to sequence, the chemical composition of the sgRNA can also affect specificity. Multiple groups have shown that introducing RNA modifications such as 2′-O-methyl-ribonucleotides, 2′-fluoro-ribonucleotides, phosphorothioate ribonucleotides and others, can increase the stability of the sgRNA by conferring resistance to nucleases, but also improve specificity by affecting the interactions between the sgRNA, DNA and Cas9(201-205). Yet another approach to sgRNA optimization involves introduction of secondary structure that can affect specificity. Recently, a study showed that engineering in a hairpin at the 5′ end of the sgRNA can alter secondary structure and thereby provide an energetic barrier to R-loop formation. This allows for greater specificity and fewer off-target effects(206). The authors also show that this method can improve the specificity of S. aureus Cas9 and Cas12a, suggesting broader applicability for altering sgRNA design(206). Each of the individual approaches to Cas optimization reviewed above have
yielded significant improvements both in specificity and efficiency of CRISPR gene editing. It will be interesting to determine whether combinations of these solutions could synergize to produce even more hyperaccurate RNPs.

Looking to the future, there are hybrid CRISPR/transposase systems that can be coopted in a similar fashion to those mentioned above for use in mammalian cells. Recent work has shown the natural occurrence of such systems in bacteria allowing for incorporation of longer fragments of DNA into the genome without the need for homology-directed repair (which requires double-stranded DNA breaks) (207, 208).

**Base editors**

The CRISPR/Cas system has been successfully used to for homology-directed recombination (HDR)-based editing of the genome. This function is critical for correcting disease-causing mutations, but the low efficiency of HDR compared with non-homologous end-joining (NHEJ) in mammalian cells complicates using this method for repairing mutations (209). Efforts to enhance usage of HDR, while significant and impactful, have only yielded moderate increases in efficiency (74, 210, 211). An elegant solution to this problem was developed by David Liu of Harvard University, who demonstrating that fusing a cytidine deaminase (enzyme which deaminates a cytosine into a uracil) with catalytically inactive Cas9 (dCas9) could result in sgRNA-guided correction of a range of C to T mutations that are relevant to human disease (212). This technology bypasses the need to make double-stranded breaks in the underlying DNA. Instead, the presence of a stretch of ssDNA in the R-loop of the dCas9 serves as a substrate for the cytidine deaminase (in this case, rat APOBEC1, which showed the highest
activity of the four enzymes tried). Importantly, in contrast with the low efficiency of HDR, deamination-driven base editing showed 15-75% efficiency with minimal indels.

The Liu lab has since taken this technology a step further and developed a parallel adenine base editor system that can convert A•T to G•C in DNA. As there are no known adenine deaminases in vivo, this endeavor required directed evolution and engineering of a transfer RNA adenosine deaminase to be able to use DNA as a substrate (61). The collection of modular base editing complexes developed by the Liu lab now enables all four transition mutations (purine to purine, or pyrimidine to pyrimidine). Since these discoveries, a number of groups have developed and/or utilized similar dCas9/deaminase base editor systems, and shown efficient base editing in organisms ranging from bacteria to organoid systems to human embryos (22, 49, 62, 93, 213-219), which is extremely promising for therapeutic applications. More recently, BE-PACE (base editors through phage-assisted continuous evolution) was used to identify and optimize base editors on both GC and non-GC target cytosines. They were able to successfully evolve three deaminases – APOBEC1, FERNY and CDA1, and showed that fusion of these evolved proteins with dCas9 enhanced base editing efficiency compared with their parental proteins(220). The authors do caution, however, that editing efficiency is subject to cell type, cell state and site specificity, meaning that each individual application may require pilot testing of a variety of base editors before the optimal one can be chosen. In addition, base editors have also been used for ex vivo applications such affinity maturation of antibodies(221).

As with all novel technology however, careful evaluation is required to avoid any unintended off-target effects. Two recent studies demonstrate that base editors, specifically cytosine base editors, cause an alarming number of unwanted, off-target mutations in vivo,
both in plants and mice (222, 223). Surprisingly, a new study found unwanted mutations in the RNA transcriptome as a result of off-target DNA base editing activity (224). Of course, some of these effects could potentially be mitigated by reducing the dose of the base editing complex that is introduced, or by refining the components of the complex. Such efforts are already underway, with examples including the use of Sniper dCas9, a Cas9 with increased specificity created by directed evolution, or RNPs instead of plasmids to reduce to delivered dose (157, 225). Furthermore, many of these off-target mutations may either be silent on non-consequential functionally, but these findings highlight the need for further research before base editors can be widely used in the clinic.

**RNA targeting**

While the development of CRISPR systems to target DNA across cell types and organisms for a variety of functions has undeniably revolutionized both basic scientific research and the development of therapeutics for clinical applications, the paramount importance of coding and non-coding RNAs in biology has made the discovery of RNA-targeting CRISPR systems an equally exciting area in the field of nucleic acid editing. Targeting of RNA by CRISPR systems is not only useful for altering levels of mRNAs and non-coding regulatory RNAs, but also represents a mechanism by which these edits can be temporally regulated, limited by the half-life of the targeted RNA (as opposed to genomic changes, which are permanent for the lifetime of the cell). While there are a number of known RNA-targeting CRISPR systems in bacteria, their adaptation for use in mammalian cell types is only now beginning to be explored (226). There are both Class 1 (multi-component) and Class 2 (single component) RNA-targeting CRISPR systems (226). Given the complexity of Class 1/Type III CRISPR systems and the resulting
difficulty in expressing functional protein complexes heterologously, the majority of uses cases for these have been in prokaryotes (226). On the other hand, Class 2 systems have been shown to target RNA, and are being successfully adapted for RNA-targeting in mammalian systems. Early work demonstrated that in the presence of a ssDNA oligonucleotide with a PAM sequence (PAMmer), SpCas9 could be ‘tricked’ into targeting ssRNAs for cleavage (227). Using a similar PAMmer-based strategy, dSpCas9 can be targeted to various mRNAs for live tracking of transcripts within the cell (228). More recently, it has been demonstrated that while the PAMmer enhances RNA-targeting of SpCas9, it is not required for this activity, as exemplified by the cleavage of repetitive RNAs and certain mRNAs (229, 230).

*S. pyogenes* is however, not the only organism with a Type II Cas9 that can be made to target RNA, and in fact, Cas9 from alternative sources have been shown to be amenable to RNA-targeting. Cas9 enzymes from *Staphylococcus aureus* (SaCas9), *Campylobacter jejuni* (CjCas9), *Francisella novicida* (FnCas9) and *Neisseria meningitidis* (NmCas9) have all been shown to have RNA-targeting activity to different extents (231-235). NmCas9 has been demonstrated to target RNAs *in vitro* in the absence of any PAMmer or co-factors, although its endogenous activity *in vivo* remains to be determined (233). CjCas9 on the other hand, has been shown to target endogenous mRNAs *in vivo* through imperfect pairing with native crRNA guides and subsequent cleavage by Cas9’s HNH domain (231). A step further is heterologous use of Cas9’s RNA-targeting activity, as shown in one study where SaCas9 had a protective effect in *E.coli* from MS2 phage through cleavage of its RNA genome, as well as targeting of endogenous *E.coli* mRNAs (234). When it comes to adaptation of these Type II Cas9s to a mammalian system, one of the few demonstrations is the use of FnCas9, which not only can target endogenous RNAs,
but has been shown to target the genome of a human RNA virus, hepatitis C, in a liver carcinoma cell line(232). If these Type II Cas9 enzymes are to be used clinically as RNA-targeting enzymes, future work should focus on efficiency and specificity (both in terms of sequence, and DNA vs RNA) in mammalian cells, with significant focus on off-target effects, as with all the other novel CRISPR systems that are discussed herein.

The issue of fine-tuning a CRISPR system to target RNA instead of DNA can be a challenge with dual-specificity Cas proteins. Another member group of the Class 2, single component CRISPR systems, the Type IV Cas13 proteins, helps bypass this difficulty by specifically targeting only RNA (not DNA). Two of the best characterized Cas13 proteins are *Leptotrichia wadei* Cas13a (LwaCas13a) and *Leptotrichia shahii* Cas13a (LshCas13a, previously known as LshC2c2), both studied by Abudayyeh and colleagues. Heterologous expression of LshCas13a was shown to degrade *E.coli* transcripts *in vivo*, as well as protect *E.coli* from MS2 phage infection(236). LwaCas13a was expressed both in plant and mammalian cells, and successfully targeted endogenous and reporter genes in both these cell types(237). Both these Cas13a proteins exhibit ‘collateral RNA cleavage’, meaning that their RNase activity causes degradation of any surrounding transcripts, and this collateral RNA cleavage is not specific for the target. This problem is circumvented by using Cas13b *Prevotella sp. P5-125* (PspCas13b), as shown by Cox et al, which exhibits specific RNase activity for its target without the collateral damage(238). This study then uses a catalytically inactive version of PspCas13b fused with ADAR2 (adenosine deaminase acting on RNA type 2) for highly specific base editing of RNA from adenosine to inosine (A to I). The authors coin their system RNA Editing for Programmable A to I Replacement, or REPAIR, and further engineer the system for optimal viral delivery(238). Future
work will likely seek to expand the repertoire of based changes that can be achieved, for example, C-to-U editing by using a fusion of Cas13 with APOBEC(239).

Another group developed a systematic computational method to identify more RNA-targeting Type IV CRISPR systems, following which they engineered seven Cas13 orthologs, which resulted in a ribonuclease effector derived from *Ruminococcus flavefaciens* XPD3002 (CasRx)(240). CasRx was used to knock down a variety of endogenous transcripts and mammalian cells with enhanced efficiency and specificity compared to RNA interference (RNAi) and even CRISPR-mediated inhibition (CRISPRi)(240). In an elegant demonstration of the therapeutic potential of their work, the authors show that CasRx can regulate the splicing of MAPT, the gene encoding the tau protein. The ratio of tau isoforms is critically mis-regulated in Frontotemporal Dementia, and CasRx can rescue this ratio in diseased cortical neurons, suggesting that this protein could potentially be used therapeutically in primary cells such as neurons, to reverse the effects of neurodegenerative disease (240). This is also an excellent example of a situation in which DNA editing would be of no use, as splicing occurs at the level of RNA. Of course, before such a therapeutic can be deployed in patients, extensive work has to be done to eliminate off-target effects and ensure long-term safety, but taken together, these RNA-targeting CRISPR systems represent a new and exciting frontier in the clinical applications of gene editing.

**CRISPR mediated repression of gene expression (CRISPRi)**

Recent modifications to the CRISPR/Cas9 system have provided effective strategies for targeted control of gene expression, as opposed to editing of nucleic acid sequences. Central to CRISPR mediated gene regulation is a mutated form of Cas9 that lacks endonuclease activity,
called dead cas9 or dCas9. The dCas9 protein incorporates point mutations (D10A and H840A) in the RuvC and HNH nuclease domains, respectively (16). Importantly, although dCas9 does not cleave DNA, it retains the ability to precisely bind specific DNA sequences through sgRNA targeting (241). Targeted gene expression can be repressed by directing dCas9 to the promoter or protein coding region of a gene. When bound to a promoter, dCas9 blocks transcription initiation through the steric inhibition of transcription factors and RNA polymerase (241) (Figure 6A). Alternatively, dCas9 bound to the protein coding region of a gene blocks transcription elongation when RNA polymerase collides with the dCas9-sgRNA complex (241).

Utilizing dCas9, or dCas9 fused to additional transcriptional repressors, to repress gene expression is the central tenet of CRISPR interference (CRISPRi).

Although dCas9 itself can be a powerful repressor of gene expression in bacteria, its ability to silence genes in mammalian cells is more modest (241, 242). Control of eukaryotic gene expression includes additional layers of regulation involving recruitment of positive and negative transcriptional regulators, as well as epigenetic modifications to genomic DNA and histones. To more effectively knock down transcription in mammalian cells, the dCas9 molecule was further engineered to incorporate fusions with various effector protein domains as illustrated in Figure 6A and B. Several fusions proteins were tested initially including dCas9 fused to the Krüppel-associated box domain of Kox1 (KRAB), the chromo shadow domain of HP1α (CS), the WRPW domain of Hes1, and four copies of the SIN3A domain of MAD1 (SID4X) (242, 243). Of the dCas9-repressor constructs tested, the dCas9-KRAB fusion was shown to be most effective at repressing eukaryotic gene expression, and could knock down reporter and endogenous genes 5~15-fold in human cells (242) (Figure 6B). The KRAB domain is broadly
conserved across eukaryotic C2H2 zinc finger proteins and exerts gene repression by interacting with chromatin-remodeling factors (244, 245). The dCas9-KRAB system has become the gold-standard for mammalian gene knockdown studies, and has been used for diverse purposes including mapping human gene regulatory networks (246), tuning gene expression in human pluripotent stem cells (247-249), and silencing gene expression within a mouse brain (250).

New CRISPR interference technologies continue to emerge, and novel modifications to the dCas9 scaffold have been shown to enhance the efficacy of gene silencing. A recent study screened numerous effector domains fused to dCas9 and found that a synergistic fusion of dCas9-KRAB-MeCP2 could produce a 5~60 fold reduction in gene expression when compared to dCas9 alone (251). These CRISPRi tools allow rapid knockdown of genes across diverse cell types and can silence regions of the genome that were historically difficult to target including non-coding RNAs, antisense transcripts and microRNAs.

**CRISPR mediated activation of gene expression (CRISPRa)**

The foundation of CRISPR mediated gene activation (CRISPRa) is the dCas9 protein fused to one or more transcriptional activators. There are several CRISPRa systems currently in use (Figure 6 C-F), and each builds a unique synthetic transcription factor that can be targeted to the promoter of a gene of interest with an sgRNA. The first version of CRISPRa involved dCas9 fused to VP64, a strong transcriptional activator composed of tetrameric repeats of the activation domain of herpes simplex viral protein VP16 (193, 242, 252, 253) (Figure 6C). The use of dCas9-VP64 has been shown to allow activation of target genes, although the level of gene expression is typically a modest 2~5 fold increase in mammalian cells (254). Interestingly, multiplexing several sgRNAs that tile the promoter enhances gene activation, suggesting that
recruitment of multiple dCas9-VP64 activators could increase gene expression (252, 255). To recruit multiple copies of VP64 to a genomic locus, a novel CRISPRa system termed SunCas9, or SunTag, was developed (256, 257) (Figure 6D). The SunTag module involves dCas9 fused to a protein scaffold composed of 10-24 repeating GCN4 peptide epitopes (256, 257). The SunTag epitope array then recruits multiple copies of the nuclear localized GCN4 scFv (single-chain variable fragment) antibody fused to a VP64 activator. Using the SunTag system a single dCas9 molecule is capable of recruiting numerous copies of VP64 to a target sequence, and considerably increases gene expression when compared to activation with the dCas9-VP64 fusion alone (257).

The next iterations of CRISPRa technologies involved combining multiple synergistic transcriptional activators with the sgRNA-directed dCas9. In one study, researchers surveyed the effects of numerous activation domains fused individually, and in combination, to dCas9 to increase gene activation (258). A tripartite activator complex composed of VP64, p65, and Rta fused in tandem, called VPR, was shown to increase gene expression of endogenous targets 22-320 fold when compared to dCas9-VP64 only (258) (Figure 6E). Another CRISPRa approach called the Synergistic Activation Mediator (SAM) builds on the dCas9-VP64 fusion protein by adding multiple, distinct activation mechanisms (259) (Figure 6F). Analysis of the crystal structure of the Cas9-sgRNA complex revealed that both the tetraloop and stem-loop 2 of the sgRNA have 4 base-pairs that inertly protrude outside of the Cas9 protein (183). The exposed sgRNA loops were hypothesized to be capable of acting as scaffolds to recruit additional transcriptional activators. The SAM system utilizes the original dCas9-VP64 protein but incorporates an engineered sgRNA that contains minimal hairpin aptamers appended to the
sgRNA tetraloop and stem-loop 2 (259). The hairpin RNA aptamers can be selectively bound by an MS2 bacteriophage coat protein (260). The MS2 protein is then fused to two additional transcriptional activators, p65 and the activation domain from the human heat-shock factor HSF1 (259). Each sgRNA aptamer can bind two copies of the MS2 protein, thus allowing a total of four copies of MS2-p65-HSF1 fusion proteins to be recruited to each dCas9-VP64 activator complex (259). Together, the SAM system utilizes a synergy of three distinct activation domains (VP64, p65 and HSF1) to generate a specific and powerful CRISPRa tool capable of activating genes more strongly than dCas9-VP64 by itself. CRISPRa technologies continue to be improved, but currently the SunTag, VPR, and SAM systems function relatively equally in terms of gene activation (261). Importantly, across diverse eukaryotic species, the SunTag, VPR, and SAM systems are all capable of gene activation several orders of magnitude stronger than the first-generation dCas9-VP64 alone (261).

While most studies utilizing CRISPRa technologies in disease models have been focused on understanding how genes function at a cellular level, several studies have looked at the potential to use CRISPRa to modulate disease in mouse models. Use of CRISPRa systems resulted in increased gene expression that led to phenotypic changes in the mice, including mouse models of diabetes, muscular dystrophy, and acute kidney disease (262). Recently, delivery of dCas9-VP64 targeted to downregulated genes in breast cancer resulted in increased gene expression and reduction of tumor growth in mouse xenografts (263). Viral based delivery of dCas9-VP64 has also been demonstrated to overcome haploinsufficiency in two obese mouse models. The resulting increase in expression from the existing normal copy of two
different genes, Sim1 or Mc4r, prevented the development of obesity in the mouse models (264).

**Epigenetic modifications using CRISPR tools**

The CRISPRi/a tools described above primarily function by directly recruiting or interfering with transcriptional machinery which is thought to result in short term alteration of gene expression limited to the duration of the CRISPRi or CRISPRa expression. However, most eukaryotes utilize additional epigenetic modifications to DNA and histones that are important regulators of gene expression. One of the most well studied epigenetic modifications is the methylation of the fifth position of cytosine. In mammals, methylation can be deposited *de novo* by DNA methyltransferase (DNMT3A/B) and can be maintained by DNMT1 (265). Demethylating DNA involves oxidation of the methyl group by TET dioxygenases, and restored by replication-dependent dilution or DNA glycosylase-initiated base excision repair (266). Methylated DNA regulatory elements interfere with their trans-acting transcription factors causing gene repression (267). The ability to edit the methylation at specific genomic loci would be a powerful capability to enable researchers to better control transcription in mammalian cells.

Targeted editing of DNA methylation has previously been accomplished with custom ZFPs or TALEs fused to DNA methyltransferases (268, 269). However, designing new ZFPs or TALEs for every target sequence of interest would be expensive and laborious. Alternatively, several CRISPR/Cas9 tools have recently been engineered that allow editing of DNA methylation, and only require a custom sgRNA for targeting to genomic loci of interest. The first generation of CRISPR-based methylation systems in mammalian cells used dCas9 fused to
full-length DNMT3a, or the DNMT3a catalytic domain (270-273). Importantly, these dCas9-based methylation tools have been shown to function with higher efficacy and resolution, and also more effectively silence gene expression than the TALE-based approaches (271-273). The dCas9-DNMT3A fusions can accurately methylate DNA across a region of ~35-320 bp from the DNA-bound fusion protein and can be multiplexed with several sgRNAs to span a larger target region of the genome (270-272). Alternatively, methylation across a larger genomic region can be edited using the dCas9-SunTag-DNMT3A system, that can recruit multiple DNMT3As to a target site and hypermethylated a region of ~4.5 kb (274, 275). Multimerization can also improve methylation and using dCas9-DNMT3a/DNMT3L could lead to more potent and widespread DNA methylation of CpG islands, and additionally caused DNA methylation spreading from a target site (276). Importantly, it is heritable across mitotic divisions (270).

One limitation to the first generation dCas9-DNMT fusion proteins is that they function relatively slowly over a period of several days, which may impede experimental systems that require analyses over shorter time durations. Additionally, recent analyses of genome-wide methylation patterns arising from dCas9-DNMT systems identified numerous off-target effects that are common in promoters, CpG islands and 5’ untranslated regions (277, 278). Off target effects of dCas9-DNMT3A may arise because dCas9 is not required to be bound to its sgRNA-target sequence in order to function, so dCas9-DNMT3A bound to other genomic loci are free to promote methylation (279). Additional off target effects may arise because DNMT3A functions as a tetramer and can recruit endogenous DNMT3A/DNMT3L proteins to methylate larger regions (270). Several recent iterations of dCas9 DNA methyltransferases have attempted to increase enzyme kinetics and resolve off target effects. To increase the rate of
DNA methylation, new CRISPR tools incorporated an engineered de novo CpG DNA methyltransferase from the bacterial species Mollicutes spiroplasma strain MQ1 (M.sssI) (280). The modified MQ1Q147L DNA methyltransferase is relatively small in size (386 amino acids), functions rapidly within 24 hours, and produces fewer off-target effects (280). The dCas9-MQ1Q147L fusion protein was demonstrated to efficiently methylate target DNA sequences in human cells and developing mouse embryos (280). Bacterial derived MTases are not expected to recruit endogenous mammalian MTases which may help to limit off-target demethylation.

To further reduce off-target events, a split version of the M.sssI MTase was shown to generate efficient and targeted DNA methylation (up to ~70%) (279). The split MTase system involves one fragment of M.sssI fused to dCas9 which then directs the assembly of the MTase fragments when bound to target DNA loci (279). Additionally, this system further reduces off target events because the two M.SssI fragments lack stability or ability to methylate DNA when dCas9 is not bound to DNA (279).

Targeted demethylation in mammalian genomes has also been accomplished with several technical variations, but all methods described here involve recruiting the TET1 dioxygenase to specific genomic loci guided by sgRNA and dCas9. Similar to the methylation strategies described above, targeted demethylation was previously demonstrated using TALE-TET1 fusions proteins in human cells (281). CRISPR-based demethylation editors subsequently emerged that involved protein fusions with dCas9 and the catalytic domain of TET1 (TET1CD), and these dCas9-TET1 systems both demethylated target DNA and activated gene expression in cancer cell lines, mouse embryonic stem cells, mouse cortical neurons, and in vivo in mice (272, 282-284). The dCas9-TET1 fusion protein was directly compared to a TALE-TET1 fusion, and the
CRISPR-based approach was determined to demethylate DNA more effectively and accurately than the TALE-based approach (28% decreased methylation within 150 bp vs. 14% within 200 bp, respectively) (272). A second CRISPR-based demethylation method involved repurposing the SunTag system to recruit multiple TET1CD molecules to a genomic locus (283). The SunTag-TET1 system was capable of more long-range demethylation when compared to TALE-based methods, likely because up to 10 copies of TET1 could be recruited to a target sequence (283). The SunTag-TET1 system was also shown to more effectively demethylate DNA than the direct dCas9-TET1CD fusion protein (>90% max observed demethylation vs. 14%, respectively) (283).

Importantly, in addition to demethylating DNA, the SunTag-TET1CD was also demonstrated to modify gene expression, and could induce a 1.7-50 fold upregulation of target genes in diverse mammalian cell types and in vivo in brain of mouse fetuses (283). Finally, a third demethylation approach repurposed the SAM system to recruit MS2-TET1CD to the MS2 aptamers protruding from the dCas9-sgRNA complex (284). The MS2-TET1CD demethylation system was also shown to promote demethylation and activate gene expression, although it was not as effective as the SunTag system (283, 284).

Together there are many variations of CRISPR-based DNA methylation editors, however in order to construct a desired epigenetic landscape, the cooperation between methylation and demethylation editors is likely necessary. For example, a recent study using mouse embryonic stem cells demonstrated that a synergy between TET1 and DNMTs was necessary to properly define and edit regions of genome methylation (285).

Altering the state of chromatin through modifications to histone proteins is another epigenetic mechanism to control proper gene expression in eukaryotes. Numerous histone modifications are involved with directing mammalian gene expression, but the majority of
current CRISPR-based histone editing involves acetylation or methylation of lysine residues. When terminal lysine residues of histone proteins are acetylated, their charge becomes more neutral which weakens the interaction between histones and DNA and can subsequently become more permissive for transcription (286). Permissive and repressive chromatin states are mediated in part by histone acetyltransferases and histone deacetylases, and these enzymes have been repurposed into novel CRISPR tools. The first CRISPR-based histone modifier was dCas9 fused to the catalytic core of the human histone acetyltransferase p300 (dCas9\(^{p300\text{ Core}}\)) (287). Notably, use of dCas9\(^{p300\text{ Core}}\) could significantly increase target gene expression in human cells due to acetylation of H3K27 residues from gene promoters as well as both proximal and distal enhancers (287). Additionally, the dCas9 transcriptional activators described above typically require the recruitment of multiple effector domains or multiple sgRNAs to promote robust gene expression, while the dCas9\(^{p300\text{ Core}}\) system needs only a single gRNA to function effectively (287). CRISPR-mediated histone deacetylation tools have also been developed using dCas9 fused to the full-length human histone deacetylase HDAC3 (288). Importantly, the dCas9-HDAC3 fusion protein was demonstrated to remove H3K27ac marks when positioned properly in a gene promoter, and could modify gene expression in mouse and human cell lines (288). Unlike the dCas9-based transcriptional activators/repressors, the positioning of the sgRNA relative to the transcription start site of a gene does not appear to influence function, however the positioning relative to endogenous histone acetylation was crucial (288).

Another modification to histone proteins that regulates chromatin accessibility and local gene expression is the methylation of lysine residues. Histone modifying enzymes including
methyltransferases and demethylases are conserved proteins that control histone methylation and can be engineered to be used as programmed histone-modifying enzymes. Recent developments to the CRISPR-based epigenetic toolbox includes both histone demethylases and methyltransferases fused to dCas9. The human protein LSD1 is a broadly conserved lysine-specific histone demethylase and transcriptional co-repressor, and silences enhancer elements through H3K4/K9 specific demethylation (289-291). An engineered TALE-LSD1 was shown to edit active enhancers and modify gene expression (292). Soon afterwards, a dCas9-LSD1 fusion protein was developed that could allow for more high-throughput histone demethylation editing (293). The dCas9-LSD1 protein was demonstrated to effectively remove histone methylation from enhancer regions and knock down gene expression in mouse embryonic stem cells (293). Alternatively, methylation of specific lysine residues on histone 3 proteins (e.g. H3K4me3 and H3K79me2-3) are associated with transcriptionally active euchromatin (291). PRDM9 is a histone lysine methyltransferase that possesses mono-, di-, and tri-methylation activities at H3K4 residues (294). The functional domain of the human PRDM9 was recently fused to dCas9, and could produce targeted H3K4me3 marks at promoter regions that activated expression from previously silenced genes in human cell lines (295). Methylation of other specific histone residues can alternatively create repressive chromatin (e.g. H3K9me3 and H3K27m3) leading to gene silencing (291). Recently, O’Geen et al. engineered a broad set of epigenetic writers and recruiters fused to dCas9, and investigated their ability to edit H3K9me3 and H3K27me3 marks and to modify gene expression (296). Interestingly, this work demonstrated that all of the methyltransferases tested (EZH2, G9A, SUV39H1 and FOG1) were all capable of some level of transcriptional repression, although they did not always correlate
with expected histone modifications (296). Additionally, some of the epigenetic editors tested only provided temporary silencing, but combinations of effectors could overcome this transient effect and promoted long-lasting repression (296). Engineering a desired and persistent cell state is a complex and challenging effort and will likely require the use of multiplexed epigenetic modifiers targeted to both enhancer and promoter regions.

Similar to the status with CRISPRi and CRISPRa technologies, the application of Cas9 epigenome editors has mostly been pursued in vitro to date. However, the potential to selectively silence a mutated gene or activate the healthy gene copy with long duration effects has vast potential in medicine that could be achieved as CRISPR epigenome editing technology advances.

**CONCLUSIONS**

The rapid development of gene editing technologies within the last decade is already providing significant advances towards improving human health. Gene editors are being used in ongoing clinical trials to treat diverse human diseases including HIV, cancer, and blood disorders. As gene editing tools continue to evolve, novel therapies for additional diseases will likely emerge. CRISPR-based gene editing tools, in particular, are quickly developing and have been used to generate diverse modifications in mammalian cells, including targeted editing of specific DNA sequences, activation or repression of genes of interest, and epigenetic reprogramming of cellular identities. However, despite the potential benefits of using gene editing technologies for human therapy, the fundamental biology underlying these technologies needs to be better understood in order to provide safe and effective treatment
options to patients. Many of the CRISPR tools have been tested only \textit{in vitro} and an outstanding question is the efficacy and safety during in vivo applications. This will likely involve the complex interplay between a given tool’s molecular function combined with the delivery modality. Some CRISPR components have been immunogenic in certain individuals – how can we engineer these potential therapies to minimize the risk of eliciting a counterproductive immune response? CRISPR gene-editing tools often exhibit widespread off-target effects, which could be dangerous if these therapies are needed in vital organs or are delivered there unintentionally – how can we maximize delivery to targeted body sites and minimize accumulation at off-target sites? These issues are all currently being investigated by research groups across the globe, and improvements in these areas will be crucial for the success of gene-editing therapies.

Ethical issues also arise from this recent wave of new gene-editing tools. Is it ethical to edit a developing human embryo? Who should make these decisions, and who will regulate them? There will need to be global discussions bridging science and politics to govern the use of CRISPR and gene editing in developing babies. Furthermore, health and disease are often a spectrum rather than a binary condition, and decisions must be made on the basis of known or likely trade-offs. Gene editing carries significant risks, such that a balance between acceptable risk for significant benefit must be struck in each case of potential use. This balance will shift as the technology advances, changing the risk/benefit profile for a given therapy.

Finally, as new technologies emerge there is always the possibility that they will be accidentally or intentionally misused. Ongoing work to identify and engineer anti-CRISPRs, such as that comprising DARPA’s Safe Genes program, is already revealing the path forward to
development of countermeasures that inhibit or reverse unwanted gene editing. Gene editing
technologies are extremely powerful and hold immense potential to provide new opportunities
to treat a myriad of human diseases. As the amount of resources devoted towards better
understanding and characterization of these technologies continues to increase dramatically
with every passing year, their full-fledged clinical deployment appears very close to becoming a
reality.

**Abbreviations**

zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), clustered
regularly interspaced short palindromic repeat DNA sequences (CRISPR), U.S. Food and Drug
Administration (FDA), investigational new drug application (IND), investigational device
exemption (IDE), tumor-infiltrating lymphocytes (TILs), T cell receptor (TCR), Adoptive T cell
transfer (ACT), Programmed cell death protein 1 (PD-1), chimeric antigen receptor (CAR), TCR α
constant (TRAC), graft-versus-host disease (GvHD), TCR β constant (TRBC), human leukocyte
antigen (HLA), β-2 microglobulin (B2M), Programmed cell death protein 1 ligand (PD-L1), β
globin gene (HBB), Hereditary Persistence of Fetal Hemoglobin (HPFH), adeno-associated virus
integration site 1 (AAVS1), Leber congenital amaurosis type 10 (LCA10), Zinc Finger Protein
(ZFP), Transcription activator-like effector proteins (TALEs), primary immunodeficiencies (PIDs),
X-linked severe combined immunodeficiency (SCID-X1), chronic granulomatous disease (CGD),
Wiskott-Aldrich syndrome (WAS), interleukin-2 receptor subunit gamma (IL2RG), cone–rod
dystrophy (CORD6), Alpha-1 Antitrypsin Deficiency (AATD), Chronic Obstructive Pulmonary
Disease (COPD), lipid nanoparticle (LNP), Cystic Fibrosis (CF), Duchenne muscular dystrophy
DMD, Cystic fibrosis transmembrane conductance regulator (CTFR), ribonucleoprotein (RNP), Circularization for In vitro Reporting of CLeavage Effects (CIRCLE-seq), Discovery of In Situ Cas Off-targets and VERification by sequencing (DISCOVER-seq), Uni-directional Targeted Sequencing (UDiTaS), Phage-assisted continuous evolution (PACE), programmable DNA-binding domains (pDBD), Cas9 fusion with the FokI nuclease (fCas9), dihydrofolate reductase (DHFR), estrogen receptor (ER50), trimethoprim (TMP), 4-hydroxytamoxifen (4-HT), homology-directed recombination (HDR), catalytically inactive Cas9 (dCas9), ssDNA oligonucleotide with a PAM sequence (PAMmer), Staphylococcus aureus Cas9 (SaCas9), Campylobacter jejuni Cas9 (CjCas9), Francisella novicida Cas9 (FnCas9), Neisseria meningitidis Cas9 (NmCas9), Streptococcus pyogenes Cas9 (SpCas9), Leptotrichia wadei Cas13a (LwaCas13a), Leptotrichia shahii Cas13a (LshCas13a, previously known as LshC2c2), Prevotella sp. Cas13b (PspCas13b), adenosine deaminase acting on RNA type 2 (ADAR2), RNA Editing for Programmable A to I Replacement (REPAIR), CRISPR mediated gene inhibition (CRISPRi), Ruminococcus flavefaciens XPD3002 (CasRx), Krüppel-associated box domain of Kox1 (KRAB), chromo shadow domain of HP1α (CS), SIN3A domain of MAD1 (SID4X), CRISPR mediated gene activation (CRISPRa), single-chain variable fragment (scFv), Synergistic Activation Mediator (SAM), DNA methyltransferase (DNMT3A/B), Mollicutes spiroplasma strain MQ1 (M.sssl), catalytic domain of TET1 (TET1CD), dCas9 fused to the catalytic core of the human histone acetyltransferase p300 (dCas9³⁰⁰ Core), lysine-specific histone demethylase (LSD1),

Acknowledgements
This paper describes objective technical results and analysis. Any subjective views or opinions that might be expressed in the paper do not necessarily represent the views of the U.S. Department of Energy or the United States Government.

Authors’ contributions

MH, RK, JAT and KSB researched and wrote the manuscript. All authors contributed to the design reviewing and editing of this manuscript. All authors read and approved the final manuscript.

Conflicts of interests

The authors declare that they have no competing interests.

Funding

This work was supported by the Laboratory Directed Research and Development program at Sandia National Laboratories, a multi-mission laboratory managed and operated by National Technology and Engineering Solutions of Sandia, LLC, a wholly owned subsidiary of Honeywell International, Inc., for the US Department of Energy's National Nuclear Security Administration under contract [DE-NA0003525].
Figure legends

Figure 1. Genome editors can be used therapeutically in several ways, and both *ex vivo* and *in vivo* delivery for somatic genome editing have advanced to clinical trial. *Ex vivo*: cells can be extracted from the patient or donor modified in the laboratory and then infused into the patient. *In vivo*: delivery vehicles, including viral vectors and nanoparticles can be loaded with the genome editor and then injected into the patient either systemically, which results in liver editing primarily, or into the location of interest, for example, the eye.

Figure 2. Genome trials registered in the US Clinical Trials database by year and selected genome editor (A) or delivery method (B) and delivery method grouped by *in vivo* or *ex vivo* use (C). Some trials did not have a clear delivery methodology (labeled as unknown). These unknown delivery methods are all *ex vivo* delivery making electroporation the most likely method. Data was accessed 1/01/2020.

Figure 3. Genome editing used to enhance Adoptive Cell Transfer (ACT) of T cells for cancer therapy. A) Genome editing (highlighted by green arrows) is being explored to create universal donor T cells to serve as the basis for TCR and CAR T cell engineering. Genome editing is also being explored to enhance the survival and/or efficacy or prevent self-targeting of both natural (circulating T cells and TILs) and engineered (TCR and CAR) T cells. B) TCR engineered T cells have the addition of a second set of TCR α and TCR β genes (highlighted in red and pink) which are present in addition to the naturally occurring TCR α and TCR β genes (highlighted in blue). C) CAR engineered T cells have a chimeric cell receptor with an scFv composed of the variable heavy and light chains (V\_H and V\_L) of an antibody as the extracellular portion fused to intracellular T cell signaling domains to cause T cell activation upon interaction with the targeted cell surface marker. Genome editing is also being applied to circulating T cells collected from a patient’s blood (D) and to isolated tumor infiltrating lymphocytes (E), which utilize the native T cell targeting to destroy tumor cells.

Figure 4. Mechanisms of Cas9 immunity seen in experimental studies. Innate immunity is mediated by pattern recognition receptors present on the cell surface (shown in blue), in the endocytic vesicles (shown in green) and cytoplasm (shown in red) of phagocytic cells. Humoral immunity is mediated by antibodies which can neutralize Cas9 protein or delivery vehicles. Both IgG and IgM antibodies have been seen to Cas9 exposure. Cellular immunity is mediated by display of peptides from intracellular proteins on cell surface receptors that can be recognized by cytotoxic T cells mediating killing of Cas9 expressing cells.

Figure 5. Engineering hyperaccurate CRISPR systems. Several approaches have been used to improve the function of Cas9 proteins and reduce off-target effects. Cas9 function has been modified through the rational design and engineering of a higher fidelity nuclease, modifying the sgRNA for increased stability, directed evolution towards hyperaccuracy, or fusing Cas9 with programmable DNA-binding domains.
Figure 6. CRISPR/Cas9 regulators of gene expression. A) The nuclease dead version of Cas9, dCas9, is directed to a genomic locus with an sgRNA and inhibits transcription of a target gene. B) Fusion of the KRAB domain to dCas9 causes stronger gene repression. CRISPR-mediate gene activation (CRISPRa) involves recruiting transcriptional activators to a genomic locus using a dCas9-sgRNA scaffold. C) The simplest CRISPRa system is dCas9 fused to VP64. More complex CRISPRa systems include D) Sun-Tag, E) VPR and F) SAM, and these involve the recruitment of multiple transcriptional activators to further enhance gene expression.
| Delivery Vector | Nuclease | Phase | Target Gene and effect | Disease | Ex vivo/in vivo | Intervention | sponsor organization | country | NCT number | date posted |
|-----------------|----------|-------|------------------------|---------|----------------|--------------|---------------------|---------|-------------|-------------|
| Adenoviral vectors | ZFN | I | CCR5 knockout | HIV | ex vivo | modified CD4+ T-cells | University of Pennsylvania | USA | NCT00842634 | 2/12/2009 |
| ZFN | I | CCR5 knockout | HIV | ex vivo | modified CD4+ T-cells | Sangamo Biosciences | USA | NCT01044654 | 1/8/2010 |
| ZFN | I/II | CCR5 knockout | HIV | ex vivo | modified CD4+ T-cells | Sangamo Biosciences | USA | NCT01252641 | 12/3/2010 |
| ZFN | I/II | CCR5 knockout | HIV | ex vivo | modified CD4+ T-cells | Sangamo Biosciences | USA | NCT01543152 | 3/2/2012 |
| ZFN | I/II | CCR5 knockout | HIV | ex vivo | modified CD4+ T-cells | Case Western Reserve University | USA | NCT03666871 | 9/12/2018 |
| AAV vectors | ZFN | I | Factor IX addition at albumin locus | Hemophilia B | in vivo | ZFN mediated addition of Factor IX gene to the albumin locus of hepatocytes | Sangamo Biosciences | USA | NCT02695160 | 3/1/2016 |
| ZFN | I | α-L-iduronidase (IDUA) addition at albumin locus | MPS type I | in vivo | ZFN mediated addition of IDUA gene to the albumin locus of hepatocytes | Sangamo Biosciences | USA | NCT02702115 | 3/8/2016 |
| ZFN | I | Iduronate 2-Sulfatase (IDS) addition at albumin locus | MPS type II | in vivo | ZFN mediated addition of IDS gene to the albumin locus of hepatocytes | Sangamo Biosciences | USA | NCT03041324 | 2/2/2017 |
| Cas9 | I | removal of alternative splice site in CEP290 | Leber Congenital Amaurosis 10 | in vivo | ZFN mediated removal of intronic alternative splice site in retinal cells | Allergan & Editas Medicine, Inc. | USA | NCT03872479 | 3/13/2019 |
| Electroporation (mRNA) | ZFN | I/II | CCR5 knockout | HIV | ex vivo | modified CD4+ T-cells | Sangamo Biosciences | USA | NCT02225665 | 8/26/2014 |
| ZFN | I | CCR5 knockout | HIV | ex vivo | modified CD4+ T-cells | University of Pennsylvania | USA | NCT02388594 | 3/17/2015 |
| ZFN | I/II | CCR5 knockout | HIV | ex vivo | modified CD34+ hematopoietic stem cells | City of Hope Medical Center | USA | NCT02500849 | 7/17/2015 |
|-----|------|----------------|-----|---------|----------------------------------------|-------------------------------|-----|--------------|---------|
| ZFN | I/II | disrupt the erythroid enhancer in B-cell lymphoma/leukemia 11A (BCL11A) | β-thalassemia | ex vivo | modified hematopoietic stem cells | Sangamo Biosciences | USA | NCT03432364 | 2/14/2018 |
| ZFN | I   | CCR5 knockout | HIV | ex vivo | modified T-cells with ZFN mediated CCR5 deletion as well as the addition of CD4 CAR receptor and modified CXCR4 expression modified hematopoietic stem cells | University of Pennsylvania | USA | NCT03617198 | 8/6/2018 |
| ZFN | I/II | disrupt B-cell lymphoma/leukemia 11A (BCL11A) | sickle cell anemia | ex vivo | modified hematopoietic stem cells | Bioverativ | USA | NCT03653247 | 8/31/2018 |
| TALEN | I   | TCRα, TCRβ, CD52 knockout | Advanced lymphoid malignancy | ex vivo | CD19-CAR modified T-cells with CAR delivered by lentivirus and TALEN knock out CD52 and TCR to create universal T-cells | Institut de Recherches Internationales Servier | UK, USA, France | NCT02746952 | 4/21/2016 |
| TALEN | I   | TCRα, TCRβ, CD52 knockout | refractory B-ALL | ex vivo | CD19-CAR modified T-cells with CAR delivered by lentivirus and TALEN knock out CD52 and TCR to create universal T-cells | Institut de Recherches Internationales Servier | UK, Belgium, France, USA | NCT02808442 | 6/21/2016 |
| TALEN | I   | Programmed Cell Death 1 (PD-1) & CD52 knockout | Acute Myeloid Leukemia | ex vivo | CD123-CAR modified T-cells with CAR delivered by lentivirus and TALEN mediated knockouts | Cellectis S.A. | USA | NCT03190278 | 6/16/2017 |
| TALEN/CRISPR | Programmed Cell Death 1 (PD-1) & CD52 knockout | Blastic Plasmacytoid Dendritic Cell Neoplasm | ex vovo | CD123-CAR modified T-cells with CAR delivered by lentivirus and TALEN mediated knockouts | Cellectis S.A. | USA | NCT03203369 | 6/29/2017 |
|----------|---------------------------------|-----------------------------------|--------|----------------------------------------------------------------------------------|----------------|------|----------------|-----------|
| TALEN     | Programmed Cell Death 1 (PD-1) & CD52 knockout | Acute Myeloid Leukemia            | ex vovo| CD123-CAR modified T-cells with CAR delivered by lentivirus and TALEN mediated knockouts | Cellectis S.A. | USA | NCT04106076 | 9/23/2019 |
| TALEN     | Programmed Cell Death 1 (PD-1) & CD52 knockout | Multiple Myeloma                  | ex vovo| CS-1-CAR modified T-cells with CAR delivered by lentivirus and TALEN mediated knockouts | Cellectis S.A. | USA | NCT04142619 | 10/29/2019 |
| TALEN     | Programmed Cell Death 1 (PD-1) & CD52 knockout | CD22+ B-cell Acute Lymphoblastic Leukemia | ex vovo| CD22-CAR modified T-cells with CAR delivered by lentivirus and TALEN mediated knockouts | Cellectis S.A. | USA | NCT04150497 | 11/4/2019 |
| Cas9 I/II | TCRγ, TCRβ, Beta-2 Microglobin (B2M) knockout | B cell leukemia                   | ex vovo| CD19-CAR modified T-cells with CAR delivered by lentivirus and Cas9 knock out B2M and TCR to create universal T-cells | Chinese PLA General Hospital | China | NCT03166878 | 5/25/2017 |
| Cas9 I    | TCRγ, TCRβ, PD-1 knockout             | various malignancies              | ex vovo| Cas9 mediated deletions and lentiviral transduction of NY-ESO-1 targeted TCR | University of Pennsylvania | USA | NCT03399448 | 1/16/2018 |
| Cas9 I/II | disruption of the erythroid enhancer to BCL11A gene | β-thalassemia                     | ex vovo| ex vovo modified hematopoietic stem cells | CRISPR Therapeutics | UK, Germany | NCT03655678 | 8/31/2018 |
| Gene | Method | Treatment | Delivery | Cells | Institution | Country | Trial ID | Start Date |
|------|--------|-----------|----------|-------|-------------|---------|---------|------------|
| Cas9 | I/II   | disruption of the erythroid enhancer to BCL11A gene | ex vivo | modified hematopoietic stem cells | Vertex Pharmaceuticals Incorporated & CRISPR Therapeutics | USA | NCT03745287 | 11/19/2018 |
| Cas9 | I/II   | creation of a CD19 directed T cell | ex vivo | CD19-directed T-cell immunotherapy | CRISPR Therapeutics | USA, Australia | NCT04035434 | 7/29/2019 |
| Cas9 | I      | disruption of HPK1 | ex vivo | CD19-CAR modified T-cells with CAR delivered by lentivirus and Cas9 knock out of HPK1 | Xijing Hospital | China | NCT04037566 | 7/30/2019 |
| ZFN  | I      | E7 oncogene of HPV16 and HPV18 deletion | in vivo | vaginal suppository with polymer to facilitate delivery | Huazhong University of Science and Technology | China | NCT02800369 | 6/15/2016 |
| TALEN| I      | E6 & E7 oncogene of HPV16 and HPV18 deletion | in vivo | plasmid in a gel containing a polymer to facilitate delivery | First Affiliated Hospital, Sun Yat-Sen University | China | NCT03057912 | 2/20/2017 |
| TALEN| I      | E6 & E7 oncogene of HPV16 and HPV18 deletion | in vivo | plasmid in vaginal suppository with polymer to facilitate delivery | Huazhong University of Science and Technology | China | NCT03226470 | 7/21/2017 |
| Cas9 | I      | E6 & E7 oncogene of HPV16 and HPV18 deletion | in vivo | plasmid in a gel containing a polymer to facilitate delivery | First Affiliated Hospital, Sun Yat-Sen University | China | NCT03057912 | 2/20/2017 |
| undefined, likely electroporation | Cas9 | Programmed death protein 1 (PD-1) knockout | ex vivo | modified T-cells | Peking University | China | NCT02793856 | 6/8/2016 |
| Cas9 | I/II | Programmed cell death protein 1 (PD-1) knockout | Stage IV bladder cancer | ex vivo modified T-cells | Peking University | China | NCT02863913 | 8/11/2016 |
|------|------|--------------------------------------------------|-------------------------|------------------------|----------------|--------|---------------|----------|
| Cas9 | I    | Programmed cell death protein 1 (PD-1) knockout | metastatic renal cell carcinoma | ex vivo modified T-cells | Peking University | China | NCT02867332 | 8/15/2016 |
| Cas9 | I    | Programmed cell death protein 1 (PD-1) knockout | hormone refractory prostate cancer | ex vivo modified T-cells | Peking University | China | NCT02867345 | 8/15/2016 |
| Cas9 | I/II | Programmed cell death protein 1 (PD-1) knockout | EBV positive, advanced stage malignancies | ex vivo modified T-cells selected for those targeting EBV positive cells | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | China | NCT03044743 | 2/7/2017 |
| Cas9 | II   | Programmed cell death protein 1 (PD-1) knockout | esophageal cancer | ex vivo modified T-cells | Hangzhou Cancer Center | China | NCT03081715 | 3/16/2017 |
| Cas9 | n/a  | CCR5 knockout | HIV | ex vivo modified CD34+ hematopoietic stem cells | Affiliated Hospital to Academy of Military Medical Sciences Chinese PLA General Hospital | China | NCT03164135 | 5/23/2017 |
| Cas9 | I/II | Cas9 mediated creation of CD19 and CD20 or CD19 and CD22 CAR-T cells | Leukemia | ex vivo CAR-T cells to CD19 and CD20 or CD19 and CD22 | Chinese PLA General Hospital | China | NCT03398967 | 1/16/2018 |
| Cas9 | I/II | Cytokine-induced SH2 protein (CISH) knockout | metastatic gastrointestinal epithelial cancer | ex vivo modified tumor infiltrating lymphocytes | National Cancer Institute | USA | NCT03538613 | 5/28/2018 |
| Cas9 | I    | Programmed cell death protein 1 (PD-1) and TCR knockout | mesothelin positive solid tumors | ex vivo CAR-T-cells to mesothelin with added PD-1 and TCR knockout | Chinese PLA General Hospital | China | NCT03545815 | 6/4/2018 |
| Gene Editor | Study | Intervention | Tissue/Cell Type | Ex Vivo Modified Hematopoietic Stem Cells | Institution | Country | NCT Number | Start Date |
|------------|-------|--------------|-----------------|------------------------------------------|-------------|---------|------------|-----------|
| Cas9       | I     | CD7 knockout in CD7 CAR-T cells | T cell malignancies | CAR-T cells to CD7 and knockout of native CD7 to prevent self targeting | Baylor College of Medicine | USA | NCT03690011 | 10/1/2018 |
| Cas9       | I     | correction of the hemoglobin subunit beta globulin gene | β-thalassemia | ex vivo modified hematopoietic stem cells | Allife Medical Science and Technology Co., Ltd. | not specified | NCT03728322 | 11/2/2018 |
| Cas9       | I     | Programmed cell death protein 1 (PD-1) knockout | mesothelin positive solid tumors | CAR-T-cells to mesothelin with PD-1 knockout modified tumor infiltrating lymphocytes | Chinese PLA General Hospital | China | NCT03747965 | 11/20/2018 |
| Cas9       | I/II  | Cytokine-induced SH2 protein (CISH) knockout | metastatic gastrointestinal epithelial cancer | modified CD4+ T-cells, 12 year follow up study | Masonic Cancer Center, University of Minnesota | USA | NCT04089891 | 9/13/2019 |
| ZFN        | follow up | CCR5 knockout | HIV | Modified CD4+ T-cells | Sangamo Biosciences | USA | NCT04201782 | 12/17/2019 |
| TALEN      | follow up | TCRα, TCRβ, CD52 knockout | Advanced lymphoid malignancy | CD19-CAR modified T-cells with CAR delivered by lentivirus and TALEN knock out CD52 and TCR to create universal T-cells, 15 year follow up study | Institut de Recherches Internationales Servier | UK, Belgium, France, USA | NCT02735083 | 4/12/2016 |
| Cas9       | follow up | disruption of the erythroid enhancer to BCL11A gene | β-thalassemia and severe sickle cell anemia | ex vivo modified hematopoietic stem cells. 15 year follow study | Vertex Pharmaceuticals Incorporated & CRISPR Therapeutics | US, UK, Germany | NCT04208529 | 12/23/2019 |

US clinical trials database (clinicaltrials.gov) was accessed 1/1/2020, trials not including interventions using gene editors were excluded.
Table 2. Clinical interventions using inactive genome editors as transcription factors.

| Vector          | Transcription factor type | Phase | Target Gene and effect                  | Disease                                                                 | Ex vivo/ in vivo | Intervention                      | sponsor organization                        | country | NCT number       | date posted |
|-----------------|---------------------------|-------|----------------------------------------|-------------------------------------------------------------------------|-----------------|-----------------------------------|----------------------------------------------|---------|-----------------|-------------|
| naked plasmid   | ZFP TF                    | I     | VEGF-A increased expression           | artherosclerosis and intermittent claudication (lower limb ischemia)   | in vivo         | injection into the leg            | National Heart, Lung, and Blood Institute (NHLBI) | USA     | NCT00080392     | 3/30/2004   |
| ZFP TF          | I                         | VEGF increased expression           | diabetic limb neuropathy                                               | in vivo         | injection into the leg            | Sangamo Therapeutics                        | USA     | NCT00110500     | 5/10/2005   |
| ZFP TF          | II                        | VEGF increased expression           | diabetes type 1 and 2, diabetic limb neuropathy                       | in vivo         | injection into the leg            | Sangamo Therapeutics                        | USA     | NCT00406458     | 12/4/2006   |
| ZFP TF          | II                        | VEGF increased expression           | diabetes type 1 and 2, diabetic limb neuropathy                       | in vivo         | injection into the leg            | Sangamo Therapeutics                        | USA     | NCT00476931     | 5/22/2007   |
| ZFP TF          | II                        | VEGF increased expression           | diabetes type 1 and 2, diabetic limb neuropathy                       | in vivo         | injection into the leg            | Sangamo Therapeutics                        | USA     | NCT00665145     | 4/23/2008   |
| ZFP TF          | II                        | VEGF increased expression           | Amyotrophic Lateral Sclerosis                                          | in vivo         | injection into neck, arm or leg   | Sangamo Therapeutics                        | USA     | NCT00748501     | 9/8/2008    |
| ZFP TF          | II                        | VEGF increased expression           | diabetes type 1 and 2, diabetic limb neuropathy                       | in vivo         | injection into the leg            | Sangamo Therapeutics                        | USA     | NCT01079325     | 3/3/2010    |

US clinical trials data base (clinicaltrials.gov) was accessed 1/1/2020.
REFERENCES

1. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409(6822):860-921.

2. International HapMap C. The International HapMap Project. Nature. 2003;426(6968):789-96.

3. Sayers EW, Agarwala R, Bolton EE, Brister JR, Canese K, Clark K, et al. Database resources of the National Center for Biotechnology Information. Nucleic Acids Res. 2019;47(D1):D23-D8.

4. Wellcome Trust Case Control C. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447(7145):661-78.

5. Visscher PM, Wray NR, Zhang Q, Sklar P, McCarthy MI, Brown MA, et al. 10 Years of GWAS Discovery: Biology, Function, and Translation. Am J Hum Genet. 2017;101(1):5-22.

6. Gaj T, Gersbach CA, Barbas CF, 3rd. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 2013;31(7):397-405.

7. Carroll D. Genome engineering with zinc-finger nucleases. Genetics. 2011;188(4):773-82.

8. Joung JK, Sander JD. TALENs: a widely applicable technology for targeted genome editing. Nat Rev Mol Cell Biol. 2013;14(1):49-55.

9. Mojica FJ, Diez-Villasenor C, Soria E, Juez G. Biological significance of a family of regularly spaced repeats in the genomes of Archaea, Bacteria and mitochondria. Mol Microbiol. 2000;36(1):244-6.

10. Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, Moineau S, et al. CRISPR provides acquired resistance against viruses in prokaryotes. Science. 2007;315(5819):1709-12.

11. Adli M. The CRISPR tool kit for genome editing and beyond. Nature Comm. 2018;9(1):1911.

12. Sternberg SH, Doudna JA. Expanding the Biologist’s Toolkit with CRISPR-Cas9. Mol Cell. 2015;58(4):568-74.

13. Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, et al. RNA-guided human genome engineering via Cas9. Science. 2013;339(6121):823-6.

14. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013;339(6121):819-23.
15. Wiedenheft B, Sternberg SH, Doudna JA. RNA-guided genetic silencing systems in bacteria and archaea. Nature. 2012;482(7385):331-8.

16. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337(6096):816-21.

17. Lino CA, Harper JC, Carney JP, Timlin JA. Delivering CRISPR: a review of the challenges and approaches. Drug Delivery. 2018;25(1):1234-57.

18. Hütter G, Nowak D, Mossner M, Ganepola S, Müßig A, Allers K, et al. Long-Term Control of HIV by CCR5 Delta32/Delta32 Stem-Cell Transplantation. The New England Journal of Medicine. 2009;360(7):692-8.

19. Yukl SA, Boritz E, Busch M, Bentsen C, Chun TW, Douek D, et al. Challenges in Detecting HIV Persistence during Potentially Curative Interventions: A Study of the Berlin Patient. PLOS Pathogens. 2013;9(3):e1003347.

20. Perez EE, Wang J, Miller JC, Jouvenot Y, Kim KA, Liu O, et al. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nature Biotechnology. 2008;26(7):808-16.

21. Tebas P, Stein D, Tang WW, Frank I, Wang SQ, Lee G, et al. Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV. The New England Journal of Medicine. 2014;370(10):901-10.

22. Zhang Y, Qin W, Lu X, Xu J, Huang H, Bai H, et al. Programmable base editing of zebrafish genome using a modified CRISPR-Cas9 system. Nat Commun. 2017;8(1):118.

23. Ye L, Wang J, Beyer AI, Teque F, Cradick TJ, Qi Z, et al. Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5Δ32 mutation confers resistance to HIV infection. PNAS. 2014;111(26):9591-6.

24. Allen AG, Chung CH, Atkins A, Dampier W, Khalili K, Nonnemacher MR, et al. Gene Editing of HIV-1 Co-receptors to Prevent and/or Cure Virus Infection. Frontiers in Microbiology. 2018;9:2940.

25. Khalili K, White MK, Jacobson JM. Novel AIDS therapies based on gene editing. Cell Mol Life Sci. 2017;74(13):2439–50.

26. Didigu CA, Wilen CB, Wang J, Doung J, Secreto AJ, Danet-Desnoyers GA, et al. Simultaneous zinc-finger nuclease editing of the HIV coreceptors ccr5 and ccr44 protects CD41 T cells from HIV-1 infection. Blood. 2014;123(1):61-9.
27. Liu Z, Chen S, Jin X, Wang Q, Yang K, Li C, et al. Genome editing of the HIV co-receptors CCR5 and CXCR4 by CRISPR-Cas9 protects CD4+ T cells from HIV-1 infection. Cell Biosci. 2017;7:47.

28. Yu S, Yao Y, Xiao H, Li J, Liu Q, Yang Y, et al. Simultaneous Knockout of CXCR4 and CCR5 Genes in CD4+ T Cells via CRISPR/Cas9 Confers Resistance to Both X4- and R5-Tropic Human Immunodeficiency Virus Type 1 Infection. Human Gene Therapy. 2018;29(1):51-67.

29. Kaminski R, Bella R, Yin C, Otte J, Ferrante P, Gendelman HE, et al. Excision of HIV-1 DNA by Gene Editing: A Proof-of-Concept In Vivo Study. Gene Ther. 2016;23(8-9):690-5.

30. Dash PK, Kaminski R, Bella R, Su H, Mathews S, Ahooyi TM, et al. Sequential LASER ART and CRISPR Treatments Eliminate HIV-1 in a Subset of Infected Humanized Mice. Nat Commun. 2019;10(1):2753.

31. Cyranoski D. First trial of CRISPR in people. Nature 2016;535(7630):479.

32. Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Annals of Oncology. 2015;26(12):2375-91.

33. Gong J, Chehrazi-Raffle A, Reddi S, Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. Journal for Immunotherapy of Cancer. 2018;6(1):8.

34. Lu Y, Huang M, Deng T, Zhou X, Yu K, Liang M, et al. A phase I trial of PD-1 deficient engineered T cells with CRISPR/Cas9 in patients with advanced non-small cell lung cancer with PD-L1 expression [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR;. Cancer Res. 2018;78(13 Suppl):Abstract nr CT133.

35. Lu Y, Xue J, Deng T, Zhou X, Yu K, Huang M, et al. A phase I trial of PD-1 deficient engineered T cells with CRISPR/Cas9 in patients with advanced non-small cell lung cancer. Journal of Clinical Oncology. 2018;36(no. 15_suppl):3050.

36. Rohaan MW, van den Berg JH, Kvistborg P, Haanen JBAG. Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option. Journal for Immunotherapy of Cancer. 2018;6:102.

37. Geukes Foppen MH, Donia M, Svane IM, Haanen JBAG. Tumor-infiltrating lymphocytes for the treatment of metastatic cancer. Molecular Oncology. 2015;9(10):1918-35.

38. Tran E, Ahmadzadeh M, Lu YC, Gros A, Turcotte S, Robbins PF, et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science. 2015;350(6266):1387-90.
39. Palmer DC, Guittard GC, Franco Z, Crompton JG, Eil RL, Patel SJ, et al. Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance. J Exp Med. 2015;212(12):2095-113.

40. Beane JD, Lee G, Zheng Z, Mendel M, Abate-Daga D, Bharathan M, et al. Clinical Scale Zinc Finger Nuclease-mediated Gene Editing of PD-1 in Tumor Infiltrating Lymphocytes for the Treatment of Metastatic Melanoma. Molecular Therapy. 2015;23(8):1380-90.

41. Barrett DM, Grupp SA, June CH. Chimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall Street. J Immunol. 2015;195(3):755-61.

42. Fesnak AD, June CH, Levine BL. Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer. 2016;16(9):566-81.

43. June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361-5.

44. Garrido F, Aptsiauri N, Doorduijn EM, Garcia Lora AM, van Hall T. The urgent need to recover MHC class I in cancers for effective immunotherapy. Current Opinion in Immunology. 2016;39:44-51.

45. Karpanen T, Olweis J. T-cell receptor gene therapy e ready to go viral? Molecular Oncology. 2015;9:2019-42.

46. Thomas R, Al-Khadairi G, Roeland J, Hendrickx W, Dermime A, Bedognetti D, et al. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives. Frontiers in Immunology. 2018;9:947.

47. Milone MC, Bhoj VG. The Pharmacology of T Cell Therapies. Molecular Therapy: Methods & Clinical Development. 2018;8:210–21.

48. Zhao J, Song Y, Liu D. Clinical trials of dual-targeted CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia. Journal of Hematology & Oncology. 2019;12(1):17.

49. Zheng K, Wang Y, Li N, Jiang FF, Wu CX, Liu F, et al. Highly efficient base editing in bacteria using a Cas9-cytidine deaminase fusion. Commun Biol. 2018;1:32.

50. Jin C, Fotaki G, Ramachandran M, Nilsson B, Essand M, Yu D. Safe engineering of CAR T cells for adoptive cell therapy of cancer using long-term episomal gene transfer. EMBO Molecular Medicine. 2016;8(7):702-11.

51. Hacein-Bey-Abina S, Garrigue A, Wang GP, Soulier J, Lim A, Morillon E, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest. 2008;118(9):3132-42.
52. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulfraat N, Leboulch P, et al. LMO2-Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1. Science. 2003;302(5644):415-19.

53. Avedillo Diez I, Zychlinski D, Coci EG, Galla M, Modlich U, Dewey RA, et al. Development of Novel Efficient SIN Vectors with Improved Safety Features for Wiskott Aldrich Syndrome Stem Cell Based Gene Therapy. Molecular Pharmaceutics. 2011;8:1525-37.

54. Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl Y, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nature Medicine. 2006;12(4):401-9.

55. Modlich U, Navarro S, Zychlinski D, Maetzig T, Knoess S, Brugman MH, et al. Insertional Transformation of Hematopoietic Cells by Self-inactivating Lentiviral and Gammaretroviral Vectors. Molecular Therapy. 2009;17(11):1919-28.

56. Osborn MJ, Webber BR, Knipping F, Lonetree C, Tennis N, DeFeo AP, et al. Evaluation of TCR Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL Nuclease. Molecular Therapy. 2016;24(3):570-81.

57. Eyquem J, Mansilla-Soto J, Giavridis T, van der Stegen SJC, Hamieh M, Cunanan KM, et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature. 2017;543:113-7.

58. Qasim W, Zhan H, Samarasinghe S, Adams S, Amrolia P, Stafford S, et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Science Translational Medicine. 2017;9(374):eaaj2013.

59. Roth TL, Puig-Saus C, Yu R, Shifrut E, Carnevale J, Li PJ, et al. Reprogramming human T cell function and specificity with non-viral genome targeting. Nature. 2018;559(7714):405-9.

60. Smith M, Zakrzewski J, James S, Sadelain M. Posttransplant chimeric antigen receptor therapy. Blood. 2018;131(10):1045-52.

61. Gaudelli NM, Komor AC, Rees HA, Packer MS, Badran AH, Bryson DI, et al. Programmable base editing of A*T to G*C in genomic DNA without DNA cleavage. Nature. 2017;551(7681):464-71.

62. Komor AC, Zhao KT, Packer MS, Gaudelli NM, Waterbury AL, Koblan LW, et al. Improved base excision repair inhibition and bacteriophage Mu Gam protein yields C:G-to-T:A base editors with higher efficiency and product purity. Sci Adv. 2017;3(8):eaa04774.

63. Ren J, Liu X, Fang C, Jiang S, June CH, Zhao Y. Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition. Clin Cancer Res. 2016;23(9):2255-66.
64. Poirot L, Philip B, Schiffer-Mannioui C, Le Clerre D, Chion-Sotinel I, Dernaime S, et al. Multiplex Genome-Edited T-cell Manufacturing Platform for "Off-the-Shelf" Adoptive T-cell Immunotherapies. Cancer Res. 2015;75(18):3853-64.

65. Gomes-Silva D, Srinivasan M, Sharma S, Lee CM, Wagner DL, Davis TH, et al. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood. 2017;130(3):285-96.

66. Haanen J, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv119-iv42.

67. Chong EA, Melenhorst JJ, Lacey SF, Ambrose DE, Gonzalez V, Levine BL, et al. PD-1 blockade modulates chimeric antigen receptor (CAR)–modified T cells: refueling the CAR. Blood. 2017;129(8):1039-41.

68. Locke FL, Westin JR, Miklos DB, Herrara AF, Jacobson CA, Lee J, et al. Phase 1 Results from ZUMA-6: Axicabtagene Ciloleucel (axi-cel; KTE-C19) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma (DLBCL). Blood. 2017;130(Suppl 1):2826.

69. Jacobson CA, Locke FL, Miklos DB, Herrara AF, Westin JR, Lee J, et al. End of Phase 1 Results from Zuma-6: Axicabtagene Ciloleucel (Axi-Cel) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma. Biol Blood Marrow Transplant. 2019;25(3):S173.

70. Hu W, Zi Z, Jin Y, Li G, Shao K, Cai Q, et al. CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelial-targeted CAR T cell effector functions. Cancer Immunology, Immunotherapy. 2019;68:365077.

71. Rupp LJ, Schumann K, Roybal KT, Gate RE, Ye CJ, Lim WA, et al. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Scientific Reports. 2017;7:737.

72. Cavazzana-Calvo M, Payen E, Negre O, Wang G, Hehir K, Fusil F, et al. Transfusion independence and HMGA2 activation after gene therapy of human b-thalassaemia. Nature. 2010;467:318-22.

73. Milone MC, O'Doherty U. Clinical use of lentiviral vectors. Leukemia. 2018;32(7):1529-41.

74. Cai L, Bai H, Mahairaki V, Gao Y, He C, Wen Y, et al. A Universal Approach to Correct Various HBB Gene Mutations in Human Stem Cells for Gene Therapy of Beta-Thalassemia and Sickle Cell Disease. Stem Cells Translational Medicine. 2018;7:87-97.
75. Ou Z, Niu X, He W, Chen Y, Song B, Xian Y, et al. The Combination of CRISPR/Cas9 and iPSC Technologies in the Gene Therapy of Human β-thalassemia in Mice. Scientific Reports. 2016;6:32463.

76. Wattanapanitch M, Damkham N, Potirat P, Trakarnsanga K, Janan M, U-pratya Y, et al. One-step genetic correction of hemoglobin E/beta-thalassemia patient-derived iPSCs by the CRISPR/Cas9 system. Stem Cell Research & Therapy. 2018;9:46.

77. Xie F, Ye L, Chang JC, Beyer Al, Wang J, Muench MO, et al. Seamless gene correction of b-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac. Genome Res. 2014;24(9):1526-33.

78. Patsali P, Turchiano G, Papasavva P, Romito M, Loucari CC, Stephanou C, et al. Correction of IVS I-110(G>A) b-thalassemia by CRISPR/Cas- and TALEN-mediated disruption of aberrant progenitor cells. haematologica. 2019;104:epub ahead of print.

79. Wienert B, Martyn GE, Funnell APW, Quinlan KGR, Crossley M. Wake-up Sleepy Gene: Reactivating Fetal Globin for β-Hemoglobinopathies. Trends in Genetics. 2018;34(12):927-40.

80. Ye L, Wang J, Tan Y, Beyer Al, Xie F, Muench MO, et al. Genome editing using CRISPR-Cas9 to create the HPFH genotype in HSPCs: An approach for treating sickle cell disease and β-thalassemia. PNAS. 2016;113(38):10661–5.

81. Bjurström CF, Mojadidi M, Phillips J, Kuo C, Lai S, Lill GR, et al. Reactivating Fetal Hemoglobin Expression in Human Adult Erythroblasts Through BCL11A Knockdown Using Targeted Endonucleases. Molecular Therapy - Nucleic Acids. 2016;5:e351.

82. Chang KH, Smith SE, Sullivan T, Chen K, Zhou Q, West JA, et al. Long-Term Engraftment and Fetal Globin Induction upon BCL11A Gene Editing in Bone-Marrow-Derived CD34+ Hematopoietic Stem and Progenitor Cells. Molecular Therapy: Methods & Clinical Development. 2017;4:137-48.

83. Zhen S, Li X. Oncogenic Human Papillomavirus: Application of CRISPR/Cas9 Therapeutic Strategies for Cervical Cancer. Cellular Physiology and Biochemistry. 2017;44:2455-66.

84. Ren C, Li X, Mao L, Xiong J, Gao C, Shen H, et al. An effective and biocompatible polyethylenimine based vaginal suppository for gene delivery. Nanomedicine: Nanotechnology, Biology, and Medicine. 2019;epub ahead of print.

85. Ding W, Hu Z, Zhu D, Jiang X, Yu L, Wang X, et al. Zinc Finger Nucleases Targeting the Human Papillomavirus E7 Oncogene Induce E7 Disruption and a Transformed Phenotype in HPV16/18-Positive Cervical Cancer Cells. Clin Cancer Res. 2014;20:6495-503.

86. Hu Z, Ding W, Zhu D, Yu L, Jiang X, Wang X, et al. TALEN-mediated targeting of HPV oncogenes ameliorates HPV-related cervical malignancy. J Clin Invest. 2015;125(1):425-36.
87. Lao YH, Li M, Gao MA, Shao D, Chi CW, Huang D, et al. HPV Oncogene Manipulation Using Nonvirally Delivered CRISPR/Cas9 or Natronobacterium gregoryi Argonaute. Advanced Science. 2018;5:1700540.

88. Hsu DS, Kornepati AVR, Glover W, Kennedy EM, Cullen BR. Targeting HPV16 DNA using CRISPR/Cas inhibits anal cancer growth in vivo. Future Virology. 2018;13(7):475-82.

89. Yoshiba T, Saga Y, Urabe M, Uchibori R, Matsubara S, Fujiwara H, et al. CRISPR/Cas9-mediated cervical cancer treatment targeting human papillomavirus E6. Oncology Letters. 2019;17:2197-206.

90. Li H, Haurigot V, Doyon Y, Li T, Wong SY, Bhagwat AS, et al. In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature. 2011;475(7355):217-21.

91. Anguela XM, Sharma R, Doyon Y, Miller JC, Li H, Haurigot V, et al. Robust ZFN-mediated genome editing in adult hemophilic mice. Blood. 2013;122(19):3283-7.

92. Sharma R, Anguela XM, Doyon Y, Wechsler T, DeKelver RC, Sproul S, et al. In vivo genome editing of the albumin locus as a platform for protein replacement therapy. Blood. 2015;126(15):1777-84.

93. Zong Y, Wang Y, Li C, Zhang R, Chen K, Ran Y, et al. Precise base editing in rice, wheat and maize with a Cas9-cytidine deaminase fusion. Nat Biotechnol. 2017;35(5):438-40.

94. Sivalingam J, Kenanov D, Han H, Nirmal AJ, Ng WH, Lee SS, et al. Multidimensional Genome-wide Analyses Show Accurate FVIII Integration by ZFN in Primary Human Cells. Molecular Therapy. 2016;24(3):607-19.

95. Ou L, DeKelver RC, Rohde M, Tom S, Radeke R, St. Martin SJ, et al. ZFN-Mediated In Vivo Genome Editing Corrects Murine Hurler Syndrome. Molecular Therapy. 2019;27(1):178-87.

96. Laoharawee K, DeKelver RC, Podetz-Pedersen KM, Rohde M, Sproul S, Nguyen HO, et al. Dose-Dependent Prevention of Metabolic and Neurologic Disease in Murine MPS II by ZFN-Mediated In Vivo Genome Editing. Molecular Therapy. 2018;26(4):1127-36.

97. Sheridan C. Sangamo’s landmark genome editing trial gets mixed reception. Nature Biotechnology. 2018;36(10):907-8.

98. Maeder ML, Stefanidakis M, Wilson CJ, Bara R, Barrera LA, Bounoutas GS, et al. Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10. Nature Medicine. 2019;25(2):229-33.

99. Dominguez AA, Lim WA, Qi LS. Beyond editing: repurposing CRISPR–Cas9 for precision genome regulation and interrogation. Nat Rev Mol Cell Biol. 2016;17(1):5-15.
100. Thakore PI, Black JB, Hilton IB, Gersbach CA. Editing the Epigenome: Technologies for Programmable Transcriptional Modulation and Epigenetic Regulation. Nat Methods. 2016;13(2):127-37.

101. Hong A. CRISPR in personalized medicine: Industry perspectives in gene editing. Seminars in Perinatology. 2018;42:501-7.

102. Booth C, Gaspar HB, Thrasher AJ. Treating Immunodeficiency through HSC Gene Therapy. Trends in Molecular Medicine. 2016;22(4):317-27.

103. Genovese P, Schirol G, Escobar G, Di Tomaso T, Firrito C, Calabria A, et al. Targeted genome editing in human repopulating hematopoietic stem cells. Nature. 2014;510:235-40.

104. Pavel-Dinu M, Wibking V, Denjene BT, Srifa W, Mantri S, Nicolas CE, et al. Gene correction for SCID-X1 in long-term hematopoietic stem cells. Nature Comm. 2019;epub ahead of print.

105. Schirol G, Ferrari S, Conway A, Jacob A, Capo V, Albano L, et al. Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1. Science Translational Medicine. 2017;9.

106. De Ravin SS, Li L, Wu X, Choi U, Allen C, Koontz S, et al. CRISPR-Cas9 gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous disease. Science Translational Medicine. 2017;9:eaah3480.

107. De Ravin SS, Reik A, Liu PQ, Li L, Wu X, Su L, et al. Targeted gene addition in human CD34+ hematopoietic cells for correction of X-linked chronic granulomatous disease. Nature Biotechnology. 2016;34(4):424-9.

108. Dreyer AK, Hoffmann D, Lachmann N, Ackermann M, Steinemann D, Timm B, et al. TALEN-mediated functional correction of X-linked chronic granulomatous disease in patient-derived induced pluripotent stem cells. Biomaterials. 2015;69:191-200.

109. Flynn R, Grundmann A, Renz P, Hänsele W, Cowley SA, Moore MD. CRISPR-mediated genotypic and phenotypic correction of a chronic granulomatous disease mutation in human iPS cells. Experimental Hematology. 2015;43:838-48.

110. Merling RK, Sweeney CL, Chu J, Bodansky A, Choi U, Long Priel D, et al. An AAVS1-Targeted Minigene Platform for Correction of iPSCs From All Five Types of Chronic Granulomatous Disease. Molecular Therapy. 2015;23(1):147-57.

111. Sürün D, Schwäble J, Tomasovic A, Ehling R, Stein S, Kurrle N, et al. High Efficiency Gene Correction in Hematopoietic Cells by Donor-Template-Free CRISPR/Cas9 Genome Editing. Molecular Therapy: Nucleic Acids. 2018;10:1-8.
112. Gutierrez-Guerrero A, Sanchez-Hernandez S, Galvani G, Pinedo-Gomez J, Martin-Guerra R, Sanchez-Gilabert A, et al. Comparison of Zinc Finger Nucleases Versus CRISPR-Specific Nucleases for Genome Editing of the Wiskott-Aldrich Syndrome Locus. Human Gene Therapy. 2018;29(3):366-80.

113. Rodrigues GA, Shalaev E, Karami TK, Cunningham J, Slater NKH, Rivers HM. Pharmaceutical Development of AAV-Based Gene Therapy Products for the Eye. Pharm Res. 2018;36(2):29.

114. Trapani I, Auricchio A. Seeing the Light after 25 Years of Retinal Gene Therapy. Trends Mol Med. 2018;24(8):669-81.

115. McCullough KT, Boye SL, Fajardo D, Calabro K, Peterson JJ, Strang CE, et al. Somatic Gene Editing of GUCY2D by AAV-CRISPR/Cas9 Alters Retinal Structure and Function in Mouse and Macaque. Human Gene Therapy. 2019;epub ahead of print.

116. Xu C, Cho GY, Sengillo JD, Park KS, Mahajan VB, Tsang SH. Translation of CRISPR Genome Surgery to the Bedside for Retinal Diseases. Frontiers in Cell and Developmental Biology. 2018;6:46.

117. Yu W, Wu Z. In Vivo Applications of CRISPR-Based Genome Editing in the Retina. Frontiers in Cell and Developmental Biology. 2018;6:53.

118. Fuster-García C, García-García G, González-Romero E, Jaijo T, Sequedo MD, Ayuso C, et al. USH2A Gene Editing Using the CRISPR System. Molecular Therapy: Nucleic Acids. 2017;8:529-41.

119. Mianné J, Chessum L, Kumar S, Aguilar C, Codner G, Hutchison M, et al. Correction of the auditory phenotype in C57BL/6N mice via CRISPR/Cas9-mediated homology directed repair. Genome Medicine. 2016;8:16.

120. Gao X, Tao Y, Lamas V, Huang M, Yeh WH, Pan B, et al. Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents. Nature 2018;553(7687):217-21.

121. Zuris JA, Thompson DB, Shu Y, Guilinger JP, Bessen JL, Hu JH, et al. Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. Nature Biotechnology. 2015;33(1):73-80.

122. Stephens CJ, Kashentseva E, Everett W, Kaliberova L, Curiel DT. Targeted in vivo knock-in of human alpha-1-antitrypsin cDNA using adenoviral delivery of CRISPR/Cas9. Gene Therapy. 2018;25:139-56.

123. Bjursell M, Porritt MJ, Ericson E, Taheri-Ghahtfarokhi A, Clausen M, Magnusson L, et al. Therapeutic Genome Editing With CRISPR/Cas9 in a Humanized Mouse Model Ameliorates α1-antitrypsin Deficiency Phenotype. EBioMedicine. 2018;29:104-11.
124. Shen S, Sanchez ME, Blomenkamp K, Corcoran EM, Marco E, Yudkoff CJ, et al. Amelioration of Alpha-1 Antitrypsin Deficiency Diseases with Genome Editing in Transgenic Mice. Human Gene Therapy. 2018;29(8):861-73.

125. Song CQ, Wang D, Jiang T, O’Connor K, Tang Q, Cai L, et al. In Vivo Genome Editing Partially Restores Alpha1-Antitrypsin in a Murine Model of AAT Deficiency. Human Gene Therapy. 2018;29(8):853-60.

126. Finn JD, Smith AR, Patel MC, Shaw L, Youniss MR, van Heteren J, et al. A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing. Cell Reports. 2018;22:2227-35.

127. Yang HC, Chen PJ. The potential and challenges of CRISPR-Cas in eradication of hepatitis B virus covalently closed circular DNA. Virus Research. 2018;244:304-10.

128. Gilani U, Shaukat M, Rasheed A, Shahid M, Tasneem F, Arshad M, et al. The implication of CRISPR/Cas9 genome editing technology in combating human oncoviruses. Journal of Medical Virology. 2018;91:1-13.

129. Moyo B, Bloom K, Scott T, Ely A, Arbuthnot P. Advances with using CRISPR/Cas-mediated gene editing to treat infections with hepatitis B virus and hepatitis C virus. Virus Research. 2017;244:311-20.

130. Paschon V, Correia FF, Morena BC, da Silva VA, Dos Santos GB, da Silva MCC, et al. CRISPR, Prime Editing, Optogenetics, and DREADDs: New Therapeutic Approaches Provided by Emerging Technologies in the Treatment of Spinal Cord Injury. Mol Neurobiol. 2020.

131. Sondhi D, Stiles KM, De BP, Crystal RG. Genetic Modification of the Lung Directed Toward Treatment of Human Disease. Human Gene Therapy. 2017;28(1):3-82.

132. Villate-Beitia I, Zarate J, Puras G, Pedraz JL. Gene delivery to the lungs: pulmonary gene therapy for cystic fibrosis. Drug Development and Industrial Pharmacy. 2017;43(7):1071-81.

133. Xia E, Duan R, Shi F, Seigel KE, Grasemann H, Hu J. Overcoming the Undesirable CRISPR-Cas9 Expression in Gene Correction. Molecular Therapy: Nucleic Acids. 2018;13:699-709.

134. Ruan J, Hirai H, Yang D, Ma L, Hou X, Jiang H, et al. Efficient Gene Editing at Major CFTR Mutation Loci. Molecular Therapy: Nucleic Acids. 2019;16:73-81.

135. Sanz DJ, Hollywood JA, Scallan MF, Harrison PT. Cas9/gRNA targeted excision of cystic fibrosis causing deep-intronic splicing mutations restores normal splicing of CFTR mRNA. PLoS One. 2017;12(9):e0184009.

136. Bednarski C, Tomczak K, vom Hövel B, Weber WM, Cathomen T. Targeted Integration of a Super-Exon into the CFTR Locus Leads to Functional Correction of a Cystic Fibrosis Cell Line Model. PLoS One. 2016;11(8):e0161072.
137. Schwank G, Koo BK, Sasselli V, Dekkers JF, Heo I, Demircan T, et al. Functional Repair of CFTR by CRISPR/Cas9 in Intestinal Stem Cell Organoids of Cystic Fibrosis Patients. Cell Stem Cell. 2013;13:653-8.

138. Crane AM, Kramer P, Bui J, Chung WJ, Li XS, Gonzalez-Garay ML, et al. Targeted Correction and Restored Function of the CFTR Gene in Cystic Fibrosis Induced Pluripotent Stem Cells. Stem Cell Reports. 2015;4:569-77.

139. Firth AL, Menon T, Parker GS, Qualls SJ, Lewis BM, Ke E, et al. Functional Gene Correction for Cystic Fibrosis in Lung Epithelial Cells Generated from Patient iPSCs. Cell Reports. 2015;12:1385-90.

140. Lee CM, Flynn R, Hollywood JA, Scallan MF, Harrison PT. Correction of the ΔF508 Mutation in the Cystic Fibrosis Transmembrane Conductance Regulator Gene by Zinc-Finger Nuclease Homology-Directed Repair. BioResearch. 2012;1(3):99-108.

141. Min YL, Bassel-Duby R, Olson EN. CRISPR Correction of Duchenne Muscular Dystrophy. Annual Review of Medicine. 2019;70:239-55.

142. Amoasii L, Hildyard JCW, Li H, Sanchez-Ortiz E, Mireault AA, Caballero D, et al. Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy. Science. 2018;362:86-91.

143. Nelson CE, Wu Y, Gemberling MP, Oliver ML, Waller MA, Bohning JD, et al. Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy. Nature Medicine. 2019;25:427-32.

144. Yang Y, Huang Y. The CRIPSR/Cas gene-editing system—an immature but useful toolkit for experimental and clinical medicine. Animal Model Exp Med. 2019;2(1):5-8.

145. Ormond KE, Morlock DP, Scholes DT, Bombard Y, Brody LC, Faucett WA, et al. Human Germline Genome Editing. The American Journal of Human Genetics. 2017;101:167-76.

146. Lea RA, Niakan KK. Human germline genome editing. Nature Cell Biology. 2019;21:1479-89.

147. Long C, McAnally JR, Selton JM, Mireault AA, Bassel-Duby R, Olson EN. Prevention of muscular dystrophy in mice by CRISPR/Cas9–mediated editing of germline DNA. Science. 2014;345(6201):1184-8.

148. German DM, Mitalipov S, Mishra A, Kaul S. Therapeutic Genome Editing in Cardiovascular Diseases. J Am Coll Cardiol Basic Trans Science. 2019;4(1):122-31.

149. Cyranoski D. What’s Next for CRISPR Babies? Nature. 2019;566:440-2.
150. Ma H, Marti-Gutierrez N, Park SW, Wu J, Lee YL, Suzuki K, et al. Correction of a pathogenic gene mutation in human embryos. Nature. 2017;548:413-9.

151. Tang L, Zeng Y, Du H, Gong M, Peng J, Zhang B, et al. CRISPR/Cas9-mediated gene editing in human zygotes using Cas9 protein. Mol Genet Genomics. 2017;292:252-33.

152. Liang P, Xu Y, Zhang X, Ding C, Huang R, Zhang Z, et al. CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. Protein Cell. 2015;6(5):363-72.

153. Fogarty NME, McCarthy A, Snijders KE, Powell BE, Kubikova N, Blakeley P, et al. Genome editing reveals a role for OCT4 in human embryogenesis. Nature. 2017;550:67-73.

154. Greely HT. CRISPR'd babies: human germline genome editing in the 'He Jiankui affair'. Journal of Law and the Biosciences. 2019;6:111-83.

155. Ranisch R. Germline genome editing versus preimplantation genetic diagnosis: Is there a case in favour of germline interventions? Bioethics. 2020;34:60-9.

156. Cross R. CRISPR's breakthrough problem. Chemical & Engineering News. 2017;95:28-33.

157. Glass Z, Lee M, Xu Q. Engineering the Delivery System for CRISPR-Based Genome Editing. Trends in Biotechnology. 2018;36(2):173-85.

158. Chew WL. Immunity to CRISPR Cas9 and Cas12a therapeutics. WIREs Syst Biol Med. 2018;10:e1408.

159. Barbalat R, Ewald SE, Mouchess ML, Barton GM. Nucleic Acid Recognition by the Innate Immune System. Annual Review of Immunology. 2011;29:185-214.

160. Kim ST, Koo T, Jee HG, Cho HY, Lee G, Lim DG, et al. CRISPR RNAs trigger innate immune responses in human cells. Genome Res. 2018;28:367-73.

161. Wienert B, Shin J, Zelin E, Pestal K, Corn JE. In vitro-transcribed guide RNAs trigger an innate immune response via the RIG-I pathway. PLoS Biology. 2018;16(7):e2005840.

162. Charlesworth CT, Deshpande PS, Dever DP, Camarena J, Lemgart VT, Cromer MK, et al. Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nature Medicine. 2019;25:249-54.

163. Simhardt RL, McGill J, McMahon S, Wang J, Jiang H, Suana ZE. Prevalence of Pre-existing Antibodies to CRISPR-Associated Nuclease Cas9 in the USA Population. Molecular Therapy: Methods & Clinical Development. 2018;10:105-12.

164. Chew WL, Tabebordbar M, Cheng JKW, Mali P, Wu EY, Ng AHM, et al. A multifunctional AAV–CRISPR–Cas9 and its host response. Nature Methods. 2016;13(10):868-74.
165. Wagner DL, Amini L, Wenderign DJ, Burkardt LM, Akyüz L, Reinke P, et al. High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population. Nature Medicine. 2019;25:242-8.

166. Zhang XH, Tee LY, Wang XG, Huang QS, Yang SH. Off-target Effects in CRISPR/Cas9-mediated Genome Engineering. Mol Ther Nucleic Acids. 2015;4:e264.

167. Florea AM, Busselberg D. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers (Basel). 2011;3(1):1351-71.

168. Gkazi SA. Quantifying CRISPR off-target effects. Emerging Topics in Life Sciences. 2019:ETLS20180146.

169. Akcakaya P, Bobbin ML, Guo JA, Malagon-Lopez J, Clement K, Garcia SP, et al. In vivo CRISPR editing with no detectable genome-wide off-target mutations. Nature. 2018;561(7723):416-9.

170. Wienert B, Wyman SK, Richardson CD, Yeh CD, Akcakaya P, Porritt MJ, et al. Unbiased detection of CRISPR off-targets in vivo using DISCOVER-Seq. Science. 2019;364(6437):286-9.

171. Harewood L, Fraser P. The impact of chromosomal rearrangements on regulation of gene expression. Human Molecular Genetics. 2014;23:R76–R82.

172. Hasty P, Montagna C. Chromosomal rearrangements in cancer Detection and potential causal mechanisms. Molecular and Cellular Oncology. 2014;1:e29904.

173. Giannoukos G, Ciulla DM, Marco E, Abdulkerim HS, Barrera LA, Bothmer A, et al. UDiTaS, a genome editing detection method for indels and genome rearrangements. BMC Genomics. 2018;19(1):212.

174. Jung C, Hawkins JA, Jones SK, Jr., Xiao Y, Rybarski JR, Dillard KE, et al. Massively Parallel Biophysical Analysis of CRISPR-Cas Complexes on Next Generation Sequencing Chips. Cell. 2017;170(1):35-47 e13.

175. Smits AH, Ziebell F, Joberty G, Zinn N, Mueller WF, Clauder-Munster S, et al. Biological plasticity rescues target activity in CRISPR knock outs. Nat Methods. 2019.

176. Ihry RJ, Worringker KA, Salick MR, Frias E, Ho D, Theriault K, et al. p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells. Nat Med. 2018;24(7):939-46.

177. Haapaniemi E, Botla S, Persson J, Schmierer B, Taipale J. CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response. Nat Med. 2018;24(7):927-30.

178. Newton MD, Taylor BJ, Driessen RPC, Roos L, Cvetesic N, Allyjaun S, et al. DNA stretching induces Cas9 off-target activity. Nat Struct Mol Biol. 2019;26(3):185-92.
179. Aryal NK, Wasylishen AR, Lozano G. CRISPR/Cas9 can mediate high-efficiency off-target mutations in mice in vivo. Cell Death Dis. 2018;9(11):1099.

180. Yamada M, Watanabe Y, Gootenberg JS, Hirano H, Ran FA, Nakane T, et al. Crystal Structure of the Minimal Cas9 from Campylobacter jejuni Reveals the Molecular Diversity in the CRISPR-Cas9 Systems. Mol Cell. 2017;65(6):1109-21 e3.

181. Jiang F, Doudna JA. CRISPR-Cas9 Structures and Mechanisms. Annu Rev Biophys. 2017;46:505-29.

182. Nishimasu H, Cong L, Yan WX, Ran FA, Zetsche B, Li Y, et al. Crystal Structure of Staphylococcus aureus Cas9. Cell. 2015;162(5):1113-26.

183. Nishimasu H, Ran FA, Hsu PD, Konermann S, Shehata SI, Dohmae N, et al. Crystal structure of Cas9 in complex with guide RNA and target DNA. Cell. 2014;156(5):935-49.

184. Yang MY, Peng SJ, Sun RR, Lin JD, Wang N, Chen CL. The Conformational Dynamics of Cas9 Governing DNA Cleavage Are Revealed by Single-Molecule FRET. Cell Reports. 2018;22(2):372-82.

185. Slaymaker IM, Gao L, Zetsche B, Scott DA, Yan WX, Zhang F. Rationally engineered Cas9 nucleases with improved specificity. Science. 2016;351(6268):84-8.

186. Kleinstiver BP, Pattanayak V, Prew MS, Tsai SQ, Nguyen NT, Zheng Z, et al. High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature. 2016;529(7587):490-5.

187. Chen JS, Dagdas YS, Kleinstiver BP, Welch MM, Sousa AA, Harrington LB, et al. Enhanced proofreading governs CRISPR-Cas9 targeting accuracy. Nature. 2017;550(7676):407+.

188. Casini A, Olivieri M, Petris G, Montagna C, Reginato G, Maule G, et al. A highly specific SpCas9 variant is identified by in vivo screening in yeast. Nat Biotechnol. 2018;36(3):265-71.

189. Vakulskas CA, Dever DP, Rettig GR, Turk R, Jacobi AM, Collingwood MA, et al. A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells. Nat Med. 2018;24(8):1216-24.

190. Hu JH, Miller SM, Geurts MH, Tang W, Chen L, Sun N, et al. Evolved Cas9 variants with broad PAM compatibility and high DNA specificity. Nature. 2018;556(7699):57-63.

191. Tsai SQ, Wyvekens N, Khayter C, Foden JA, Thapar V, Reyon D, et al. Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing. Nat Biotechnol. 2014;32(6):569-76.

192. Guilinger JP, Thompson DB, Liu DR. Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification. Nat Biotechnol. 2014;32(6):577-82.
193. Mali P, Aach J, Stranges PB, Esvelt KM, Moosburner M, Kosuri S, et al. CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat Biotechnol. 2013;31(9):833-8.

194. Ran FA, Hsu PD, Lin CY, Gootenberg JS, Konermann S, Trevino AE, et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell. 2013;154(6):1380-9.

195. Fu Y, Sander JD, Reyon D, Cascio VM, Joung JK. Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat Biotechnol. 2014;32(3):279-84.

196. Bolukbasi MF, Gupta A, Oikemus S, Derr AG, Garber M, Brodsky MH, et al. DNA-binding-domain fusions enhance the targeting range and precision of Cas9. Nat Methods. 2015;12(12):1150-6.

197. Maji B, Moore CL, Zetsche B, Volz SE, Zhang F, Shoulders MD, et al. Multidimensional chemical control of CRISPR-Cas9. Nat Chem Biol. 2017;13(1):9-11.

198. Xu H, Xiao T, Chen CH, Li W, Meyer CA, Wu Q, et al. Sequence determinants of improved CRISPR sgRNA design. Genome Res. 2015;25(8):1147-57.

199. Wu X, Kriz AJ, Sharp PA. Target specificity of the CRISPR-Cas9 system. Quant Biol. 2014;2(2):59-70.

200. Cui Y, Xu J, Cheng M, Liao X, Peng S. Review of CRISPR/Cas9 sgRNA Design Tools. Interdiscip Sci. 2018;10(2):455-65.

201. Hendel A, Bak RO, Clark JT, Kennedy AB, Ryan DE, Roy S, et al. Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nat Biotechnol. 2015;33(9):985-9.

202. Yin H, Song CQ, Suresh S, Wu Q, Walsh S, Rhym LH, et al. Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing. Nat Biotechnol. 2017;35(12):1179-87.

203. Ryan DE, Taussig D, Steinfeld I, Phadnis SM, Lunstad BD, Singh M, et al. Improving CRISPR-Cas specificity with chemical modifications in single-guide RNAs. Nucleic Acids Res. 2018;46(2):792-803.

204. Mir A, Alterman JF, Hassler MR, Debacker AJ, Hudgens E, Echeverria D, et al. Heavily and fully modified RNAs guide efficient SpyCas9-mediated genome editing. Nat Commun. 2018;9(1):2641.

205. O'Reilly D, Kartje ZJ, Ageely EA, Malek-Adamian E, Habibian M, Schofield A, et al. Extensive CRISPR RNA modification reveals chemical compatibility and structure-activity relationships for Cas9 biochemical activity. Nucleic Acids Res. 2019;47(2):546-58.
206. Kocak DD, Josephs EA, Bhandarkar V, Adkar SS, Kwon JB, Gersbach CA. Increasing the specificity of CRISPR systems with engineered RNA secondary structures. Nat Biotechnol. 2019.

207. Strecker J, Ladha A, Gardner Z, Schmid-Burgk JL, Makarova KS, Koonin EV, et al. RNA-guided DNA insertion with CRISPR-associated transposases. Science. 2019;365(6448):48-53.

208. Klompe SE, Vo PLH, Halpin-Healy TS, Sternberg SH. Transposon-encoded CRISPR-Cas systems direct RNA-guided DNA integration. Nature. 2019;571(7764):219-25.

209. Guirouilh-Barbat J, Huck S, Bertrand P, Pirzio L, Desmaze C, Sabatier L, et al. Impact of the KU80 pathway on NHEJ-induced genome rearrangements in mammalian cells. Mol Cell. 2004;14(5):611-23.

210. Aird EJ, Lovendahl KN, St Martin A, Harris RS, Gordon WR. Increasing Cas9-mediated homology-directed repair efficiency through covalent tethering of DNA repair template. Commun Biol. 2018;1:54.

211. Lin S, Staahl BT, Alla RK, Doudna JA. Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery. Elife. 2014;3:e04766.

212. Komor AC, Kim YB, Packer MS, Zuris JA, Liu DR. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature. 2016;533(7603):420-4.

213. Kim K, Ryu SM, Kim ST, Baek G, Kim D, Lim K, et al. Highly efficient RNA-guided base editing in mouse embryos. Nat Biotechnol. 2017;35(5):435-7.

214. Ma Y, Yu L, Zhang X, Xin C, Huang S, Bai L, et al. Highly efficient and precise base editing by engineered dCas9-guide tRNA adenosine deaminase in rats. Cell Discov. 2018;4:39.

215. Yeh WH, Chiang H, Rees HA, Edge ASB, Liu DR. In vivo base editing of post-mitotic sensory cells. Nat Commun. 2018;9(1):2184.

216. Lee HK, Willi M, Miller SM, Kim S, Liu C, Liu DR, et al. Targeting fidelity of adenine and cytosine base editors in mouse embryos. Nat Commun. 2018;9(1):4804.

217. Tan J, Zhang F, Karcher D, Bock R. Engineering of high-precision base editors for site-specific single nucleotide replacement. Nat Commun. 2019;10(1):439.

218. Liang P, Xie X, Zhi S, Sun H, Zhang X, Chen Y, et al. Genome-wide profiling of adenine base editor specificity by EndoV-seq. Nat Commun. 2019;10(1):67.

219. Zafra MP, Schatoff EM, Katti A, Foronda M, Breinig M, Schweitzer AY, et al. Optimized base editors enable efficient editing in cells, organoids and mice. Nat Biotechnol. 2018;36(9):888-93.
220. Thuronyi BWK, L. W.; Levy, J. M.; Yeh, W.-H.; Zheng, C.; Newby, G. A.; Wilson, C.; Bhaumik, M.; Shubina-Oleninik, O.; Holt, J. R.; Liu, D. R. Continuous evolution of base editors with expanded target compatibility and improved activity. Nature Biotechnology. 2019.

221. Liu LD, Huang M, Dai P, Liu T, Fan S, Cheng X, et al. Intrinsic Nucleotide Preference of Diversifying Base Editors Guides Antibody Ex Vivo Affinity Maturation. Cell Rep. 2018;25(4):884-92 e3.

222. Zuo E, Sun Y, Wei W, Yuan T, Ying W, Sun H, et al. Cytosine base editor generates substantial off-target single-nucleotide variants in mouse embryos. Science. 2019;364(6437):289-92.

223. Jin S, Zong Y, Gao Q, Zhu Z, Wang Y, Qin P, et al. Cytosine, but not adenine, base editors induce genome-wide off-target mutations in rice. Science. 2019;364(6437):292-5.

224. Grunewald J, Zhou R, Garcia SP, Iyer S, Lareau CA, Aryee MJ, et al. Transcriptome-wide off-target RNA editing induced by CRISPR-guided DNA base editors. Nature. 2019.

225. Kim D, Kim DE, Lee G, Cho SI, Kim JS. Genome-wide target specificity of CRISPR RNA-guided adenine base editors. Nat Biotechnol. 2019;37(4):430-5.

226. Terns MP. CRISPR-Based Technologies: Impact of RNA-Targeting Systems. Mol Cell. 2018;72(3):404-12.

227. O’Connell MR, Oakes BL, Sternberg SH, East-Seletsky A, Kaplan M, Doudna JA. Programmable RNA recognition and cleavage by CRISPR/Cas9. Nature. 2014;516(7530):263-6.

228. Nelles DA, Fang MY, O’Connell MR, Xu JL, Markmiller SJ, Doudna JA, et al. Programmable RNA Tracking in Live Cells with CRISPR/Cas9. Cell. 2016;165(2):488-96.

229. Liu Y, Chen Z, He A, Zhan Y, Li J, Liu L, et al. Targeting cellular mRNAs translation by CRISPR-Cas9. Sci Rep. 2016;6:29652.

230. Batra R, Nelles DA, Pirie E, Blue SM, Marina RJ, Wang H, et al. Elimination of Toxic Microsatellite Repeat Expansion RNA by RNA-Targeting Cas9. Cell. 2017;170(5):899-912 e10.

231. Dugar G, Leenay RT, Eisenbart SK, Bischler T, Aul BU, Beisel CL, et al. CRISPR RNA-Dependent Binding and Cleavage of Endogenous RNAs by the Campylobacter jejuni Cas9. Mol Cell. 2018;69(5):893-905 e7.

232. Price AA, Sampson TR, Ratner HK, Grakoui A, Weiss DS. Cas9-mediated targeting of viral RNA in eukaryotic cells. Proc Natl Acad Sci U S A. 2015;112(19):6164-9.

233. Rousseau BA, Hou Z, Gramelspacher MJ, Zhang Y. Programmable RNA Cleavage and Recognition by a Natural CRISPR-Cas9 System from Neisseria meningitidis. Mol Cell. 2018;69(5):906-14 e4.
234. Strutt SC, Torrez RM, Kaya E, Negrete OA, Doudna JA. RNA-dependent RNA targeting by CRISPR-Cas9. Elife. 2018;7.

235. Sampson TR, Saroj SD, Llewellyn AC, Tzeng YL, Weiss DS. A CRISPR/Cas system mediates bacterial innate immune evasion and virulence. Nature. 2013;497(7448):254-7.

236. Abudayyeh OO, Gootenberg JS, Konermann S, Joung J, Slaymaker IM, Cox DB, et al. C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector. Science. 2016;353(6299):aaf5573.

237. Abudayyeh OO, Gootenberg JS, Essletzbichler P, Han S, Joung J, Belanto JJ, et al. RNA targeting with CRISPR-Cas13. Nature. 2017;550(7675):280-4.

238. Cox DBT, Gootenberg JS, Abudayyeh OO, Franklin B, Kellner MJ, Joung J, et al. RNA editing with CRISPR-Cas13. Science. 2017;358(6366):1019-27.

239. Kim VN. RNA-targeting CRISPR comes of age. Nat Biotechnol. 2018;36(1):44-5.

240. Konermann S, Lotfy P, Brideau NJ, Oki J, Shokhirev MN, Hsu PD. Transcriptome Engineering with RNA-Targeting Type VI-D CRISPR Effectors. Cell. 2018;173(3):665+.

241. Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP, et al. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell. 2013;152(5):1173-83.

242. Gilbert LA, Larson MH, Morsut L, Liu Z, Brar GA, Torres SE, et al. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell. 2013;154(2):442-51.

243. Konermann S, Brigham MD, Trevino A, Hsu PD, Heidenreich M, Cong L, et al. Optical control of mammalian endogenous transcription and epigenetic states. Nature. 2013;500(7463):472-6.

244. Margolin JF, Friedman JR, Meyer WK, Visser H, Thiesen HJ, Rauscher FJ, 3rd. Kruppel-associated boxes are potent transcriptional repression domains. Proc Natl Acad Sci U S A. 1994;91(10):4509-13.

245. Lupo A, Cesaro E, Montano G, Zurlo D, Izzo P, Costanzo P. KRAB-Zinc Finger Proteins: A Repressor Family Displaying Multiple Biological Functions. Curr Genomics. 2013;14(4):268-78.

246. Gasperini M, Hill AJ, McFafine-Figueroa JL, Martin B, Kim S, Zhang MD, et al. A Genomewide Framework for Mapping Gene Regulation via Cellular Genetic Screens. Cell. 2019;176(6):1516.

247. Mandegar MA, Huebsch N, Frolov EB, Shin E, Truong A, Olvera MP, et al. CRISPR Interference Efficiently Induces Specific and Reversible Gene Silencing in Human iPSCs. Cell Stem Cell. 2016;18(4):541-53.
248. Libby AR, Joy DA, So PL, Mandegar MA, Muncie JM, Mendoza-Camacho FN, et al. Spatiotemporal mosaic self-patternning of pluripotent stem cells using CRISPR interference. Elife. 2018;7.

249. Kearns NA, Genga RM, Enuameh MS, Garber M, Wolfe SA, Maehr R. Cas9 effector-mediated regulation of transcription and differentiation in human pluripotent stem cells. Development. 2014;141(1):219-23.

250. Zheng Y, Shen W, Zhang J, Yang B, Liu YN, Qi H, et al. CRISPR interference-based specific and efficient gene inactivation in the brain. Nat Neurosci. 2018;21(3):447-54.

251. Yeo NC, Chavez A, Lance-Byrne A, Chan Y, Menn D, Milanova D, et al. An enhanced CRISPR repressor for targeted mammalian gene regulation. Nat Methods. 2018;15(8):611-6.

252. Maeder ML, Linder SJ, Cascio VM, Fu Y, Ho QH, Joung JK. CRISPR RNA-guided activation of endogenous human genes. Nat Methods. 2013;10(10):977-9.

253. Perez-Pinera P, Kocak DD, Vockley CM, Adler AF, Kabadi AM, Polstein LR, et al. RNA-guided gene activation by CRISPR-Cas9-based transcription factors. Nat Methods. 2013;10(10):973-6.

254. La Russa MF, Qi LS. The New State of the Art: Cas9 for Gene Activation and Repression. Mol Cell Biol. 2015;35(22):3800-9.

255. Cheng AW, Wang H, Yang H, Shi L, Katz Y, Theunissen TW, et al. Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system. Cell Res. 2013;23(10):1163-71.

256. Gilbert LA, Horlbeck MA, Adamson B, Villalta JE, Chen Y, Whitehead EH, et al. Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation. Cell. 2014;159(3):647-61.

257. Tanenbaum ME, Gilbert LA, Qi LS, Weissman JS, Vale RD. A protein-tagging system for signal amplification in gene expression and fluorescence imaging. Cell. 2014;159(3):635-46.

258. Chavez A, Scheiman J, Vora S, Pruitt BW, Tuttle M, E PRI, et al. Highly efficient Cas9-mediated transcriptional programming. Nat Methods. 2015;12(4):326-8.

259. Konermann S, Brigham MD, Trevino AE, Joung J, Abudayyeh OO, Barcena C, et al. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature. 2015;517(7536):583-8.

260. Peabody DS. The RNA binding site of bacteriophage MS2 coat protein. EMBO J. 1993;12(2):595-600.

261. Chavez A, Tuttle M, Pruitt BW, Ewen-Campen B, Chari R, Ter-Ovanesyan D, et al. Comparison of Cas9 activators in multiple species. Nat Methods. 2016;13(7):563-7.
262. Liao HK, Hatanaka F, Araoda T, Reddy P, Wu MZ, Sui Y, et al. In Vivo Target Gene Activation via CRISPR/Cas9-Mediated Trans-epigenetic Modulation. Cell. 2017;171(7):1495-507.

263. Kretzmann JA, Evans CW, Moses C, Sorolla A, Kretzmann AL, Wang E, et al. Tumour suppression by targeted intravenous nonviral CRISPRa using dendritic polymers. Chem Sci. 2019;Advance Article.

264. Matharu N, Rattanasopha S, Tamura S, Maliskova L, Wang Y, Bernard A, et al. CRISPR-mediated activation of a promoter or enhancer rescues obesity caused by haploinsufficiency. Science. 2019;363:eaau0629.

265. Smith ZD, Meissner A. DNA methylation: roles in mammalian development. Nat Rev Genet. 2013;14(3):204-20.

266. Wu H, Zhang Y. Reversing DNA methylation: mechanisms, genomics, and biological functions. Cell. 2014;156(1-2):45-68.

267. Attwood JT, Yung RL, Richardson BC. DNA methylation and the regulation of gene transcription. Cell Mol Life Sci. 2002;59(2):241-57.

268. Siddique AN, Nunna S, Rajavelu A, Zhang Y, Jurkowska RZ, Reinhardt R, et al. Targeted methylation and gene silencing of VEGF-A in human cells by using a designed Dnmt3a-Dnmt3L single-chain fusion protein with increased DNA methylation activity. J Mol Biol. 2013;425(3):479-91.

269. Bernstein DL, Le Lay JE, Ruano EG, Kaestner KH. TALE-mediated epigenetic suppression of CDKN2A increases replication in human fibroblasts. J Clin Invest. 2015;125(5):1998-2006.

270. Vojta A, Dobrinic P, Tadic V, Bockor L, Korac P, Julg B, et al. Repurposing the CRISPR-Cas9 system for targeted DNA methylation. Nucleic Acids Res. 2016;44(12):5615-28.

271. McDonald JI, Celik H, Rois LE, Fisheberger G, Fowler T, Rees R, et al. Reprogrammable CRISPR/Cas9-based system for inducing site-specific DNA methylation. Biol Open. 2016;5(6):866-74.

272. Liu XS, Wu H, Ji X, Stelzer Y, Wu X, Czauderna S, et al. Editing DNA Methylation in the Mammalian Genome. Cell. 2016;167(1):233-47 e17.

273. Amabile A, Migliara A, Capasso P, Biffi M, Cittardo D, Naldini L, et al. Inheritable Silencing of Endogenous Genes by Hit-and-Run Targeted Epigenetic Editing. Cell. 2016;167(1):219-32 e14.

274. Huang YH, Su J, Lei Y, Brunetti L, Gundy MC, Zhang X, et al. DNA epigenome editing using CRISPR-Cas SunTag-directed DNMT3A. Genome Biol. 2017;18(1):176.
275. Pflueger C, Tan D, Swain T, Nguyen T, Pflueger J, Nefzger C, et al. A modular dCas9-SunTag DNMT3A epigenome editing system overcomes pervasive off-target activity of direct fusion dCas9-DNMT3A constructs. Genome Res. 2018;28(8):1193-206.

276. Stepper P, Kungulovski G, Jurkowska RZ, Chandra T, Krueger F, Reinhardt R, et al. Efficient targeted DNA methylation with chimeric dCas9-Dnmt3a-Dnmt3L methyltransferase. Nucleic Acids Res. 2017;45(4):1703-13.

277. Galonska C, Charlton J, Mattei AL, Donaghey J, Clement K, Gu H, et al. Genome-wide tracking of dCas9-methyltransferase footprints. Nat Commun. 2018;9(1):597.

278. Lin L, Liu Y, Xu F, Huang J, Daugaard TF, Petersen TS, et al. Genome-wide determination of on-target and off-target characteristics for RNA-guided DNA methylation by dCas9 methyltransferases. Gigascience. 2018;7(3):1-19.

279. Xiong T, Meister GE, Workman RE, Kato NC, Spellberg MJ, Turker F, et al. Targeted DNA methylation in human cells using engineered dCas9-methyltransferases. Sci Rep. 2017;7(1):6732.

280. Lei Y, Zhang X, Su J, Jeong M, Gundry MC, Huang YH, et al. Targeted DNA methylation in vivo using an engineered dCas9-MQ1 fusion protein. Nat Commun. 2017;8:16026.

281. Maeder ML, Angstman JF, Richardson ME, Linder SJ, Cascio VM, Tsai SQ, et al. Targeted DNA demethylation and activation of endogenous genes using programmable TALE-TET1 fusion proteins. Nat Biotechnol. 2013;31(12):1137-42.

282. Choudhury SR, Cui Y, Lubecka K, Stefanksa B, Irudayaraj J. CRISPR-dCas9 mediated TET1 targeting for selective DNA demethylation at BRCA1 promoter. Oncotarget. 2016;7(29):46545-56.

283. Morita S, Noguchi H, Horii T, Nakabayashi K, Kimura M, Okamura K, et al. Targeted DNA demethylation in vivo using dCas9-peptide repeat and scFv-TET1 catalytic domain fusions. Nat Biotechnol. 2016;34(10):1060-5.

284. Xu X, Tao Y, Gao X, Zhang L, Li X, Zou W, et al. A CRISPR-based approach for targeted DNA demethylation. Cell Discov. 2016;2:16009.

285. Gu T, Lin X, Cullen SM, Luo M, Jeong M, Estecio M, et al. DNMT3A and TET1 cooperate to regulate promoter epigenetic landscapes in mouse embryonic stem cells. Genome Biol. 2018;19(1):88.

286. Bannister AJ, Kouzarides T. Regulation of chromatin by histone modifications. Cell Res. 2011;21(3):381-95.
287. Hilton IB, D’Ippolito AM, Vockley CM, Thakore PI, Crawford GE, Reddy TE, et al. Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. Nat Biotechnol. 2015;33(5):510-7.

288. Kwon DY, Zhao YT, Lamonica JM, Zhou Z. Locus-specific histone deacetylation using a synthetic CRISPR-Cas9-based HDAC. Nat Commun. 2017;8:15315.

289. Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell. 2004;119(7):941-53.

290. Whyte WA, Bilodeau S, Orlando DA, Hoke HA, Frampton GM, Foster CT, et al. Enhancer decommissioning by LSD1 during embryonic stem cell differentiation. Nature. 2012;482(7384):221-5.

291. Martin C, Zhang Y. The diverse functions of histone lysine methylation. Nat Rev Mol Cell Biol. 2005;6(11):838-49.

292. Mendenhall EM, Williamson KE, Reyon D, Zou JY, Ram O, Joung JK, et al. Locus-specific editing of histone modifications at endogenous enhancers. Nat Biotechnol. 2013;31(12):1133-6.

293. Kearns NA, Pham H, Tabak B, Genga RM, Silverstein NJ, Garber M, et al. Functional annotation of native enhancers with a Cas9-histone demethylase fusion. Nat Methods. 2015;12(5):401-3.

294. Wu H, Mathioudakis N, Diagouraga B, Dong A, Dombrovski L, Baudat F, et al. Molecular basis for the regulation of the H3K4 methyltransferase activity of PRDM9. Cell Rep. 2013;5(1):13-20.

295. Cano-Rodriguez D, Gjaltema RA, Jilderda LJ, Jellema P, Dokter-Fokkens J, Ruiters MH, et al. Writing of H3K4Me3 overcomes epigenetic silencing in a sustained but context-dependent manner. Nat Commun. 2016;7:12284.

296. O’Geen H, Ren C, Nicolet CM, Perez AA, Halmai J, Le VM, et al. dCas9-based epigenome editing suggests acquisition of histone methylation is not sufficient for target gene repression. Nucleic Acids Res. 2017;45(17):9901-16.
**Ex vivo**

- Genome editing

**In vivo**

- Viral delivery
- Nanoparticle delivery

Diagram showing the comparison between ex vivo and in vivo approaches for genome editing and delivery systems.
